Regression of Fibrosis & Reversal of Diastolic 
Dysfunction in HFpEF Patients Treated With 
Allogeneic CDCs (RegressHFpEF) 
[STUDY_ID_REMOVED]
Rev. October 12, 2020  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12, 2020  
Confidential  1 October 12, 2020  , 200 
  
 
 
Item 6: Clinical Protocol: Revision #3    October 12, 2020 
 
Study Title: Regress- HFpEF:  Regression of fibrosis &  reversal  of 
diastolic dysfunction in HFpEF  patients treated with 
allogeneic  CDCs  
A Phase 2 Study of the safety and feasibility of 
intracoronary delivery of allogeneic human cardiosphere-  
derived stem  cells (CDCs)  in patients  with heart  failure  and 
a preserved ejection fraction (HFpEF ). 
 
Study Phase:  Phase 2 
 
Product  Name:  CAP- 1002, wit h allogeneic  human  cardiosphere- derived 
cells as the active ingredient  
 
Indication:  Heart failure with a preserved ejection fraction  
 
Investigators:  Michael R. Zile, MD, Sheldon Litwin, MD,  Valerian  
Fernandes, MD, Eduardo Marbán, MD, PhD  
 
Sponsor:  Eduardo Marbán, MD, PhD -  Cedars -Sinai Heart  Institute  
 
Sponsor Contact:  Cedars -Sinai Heart  Institute  
1090 Davis Building  
8700 Beverly Blvd.  
Los Angeles, CA 90048 
 
 
Date Original Protocol:  January 15, 2016 
Amendment #1:  September 6, 2017 
Amendment #2: August 3, 2020 
Amendment #3: October 12, 2020 
 
 
Confidentiality Statement  
This document is confidential and proprietary to Cedars -Sinai Medical Center and their affiliates. Acceptance of this 
document consti tutes agreement by the recipient that no unpublished information contained herein will be reproduced, 
published, or otherwise disseminated or disclosed without prior written approval of Cedars -Sinai Medical Center and all of 
their affiliates, except that this document may be disclosed in any medium to appropriate clinical investigators, Institutional 
Review Boards, and others directly involved in the clinical investigation that is the subject of this information under the 
condition that they keep the inform ation strictly confidential. 
 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12, 2020  
Confidential  2 October 12, 2020  , 200 
  
TABLE OF CONTENTS  
 
Study Synopsis                6-11 
Abbreviations              12- 14 
1.1 Rationale for Study and Patient  Population:  ............................................................ 15 
1.2. Prior Human Experience with Cardiosphere- Derived  Cells:  ................................... 16 
2. STUDY OBJECTIVES  ............................................................................................... 17 
2.1. Primary Objective  ................................................................................................... 17 
2.2. Secondary  Objective  .............................................................................................. 17 
3. STUDY ENDPOINTS  ................................................................................................ 17 
3.1 Primary  Endpoints  ............................................................................................. 17 
3.1.1  Primary  Safety  Endpoints  .......................................................................... 17 
3.1.2  Secondary Safety endpoints (Short and Long Term):  ................................ 18 
3.2 Secondary  Endpoints  ........................................................................................ 18 
3.2.1. Efficacy Endpoints (Exploratory): 6-  and 12- month follow- up periods*:  .... 18 
4. INVESTIGATIONAL  PLAN  ........................................................................................ 19 
4.1 Overall Study Design and Plan ......................................................................... 19 
4.2 Study Duration and Dates  ................................................................................. 25 
5. STUDY POPULATION SELECTION ......................................................................... 25 
5.1 Study  Population  ............................................................................................... 25 
5.2 Inclusion Criteria  ............................................................................................... 26 
5.3 Exclusion Criteria  .............................................................................................. 26 
6. STUDY TREATMENT(S)  .......................................................................................... 28 
6.1 Description of  Treatment(s)  .............................................................................. 28 
6.1.1  Study  Drug  .................................................................................................  28 
6.2 Treatment  Administered .................................................................................... 28 
6.3 Selection and Timing of Dose  ........................................................................... 29 
6.4 Method of Assigning Patients to Treatment  Groups  .......................................... 29 
6.5 Concomitant Therapy  ........................................................................................ 29 
6.6 Restrictions  ....................................................................................................... 30 
6.6.1  Prior  Therapy  ............................................................................................. 30 
6.6.2  Fluid and Food Intake ................................................................................ 30 
6.6.3  Patient  Activity  Restriction  ......................................................................... 30 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12, 2020  
Confidential  3 October 12, 2020  , 200 
 6.7 Treatment  Compliance ...................................................................................... 30 
6.8 Packaging and Labeling .................................................................................... 30 
6.9 Storage and Accountability  ............................................................................... 30 
6.10 Investigational Product Retention at  Study  Site .............................................. 31 
7. STUDY PROCEDURES ............................................................................................ 31 
7.1. Informed  Consent  ............................................................................................ 31 
7.2. Medical  History  ................................................................................................ 31 
7.3. Physical  Examination  ....................................................................................... 32 
7.4. Vital Signs  ........................................................................................................ 32 
7.4.1.  Laboratory  Parameters  ............................................................................. 32 
7.5 12-Lead ECG  .................................................................................................... 33 
7.6 Echocardiography  ............................................................................................. 33 
7.7 Holter  Monitor  ................................................................................................... 33 
7.8 Six Minute Walk Test  ........................................................................................ 33 
7.9 Magnetic Resonance Imaging Protocol  ............................................................ 33 
7.10 Image Analysis  ............................................................................................... 33 
7.11 Cardiac  CT ...................................................................................................... 33 
7.12 Clinical Functional Capacity and Quality of  Life Measures  ............................. 34 
7.13 Adverse Events  ............................................................................................... 34 
7.13.1  Timing  ...................................................................................................... 35 
7.13.2  Severity  .................................................................................................... 35 
7.13.3  Relationship ............................................................................................. 35 
7.13.4  Expectedness  .......................................................................................... 36 
7.13.5  Clinical Significance  ................................................................................. 37 
7.13.6  Clinical Laboratory  Adverse Events  ......................................................... 37 
7.13.7  Serious  Adverse  Events  .......................................................................... 38 
7.13.7.1  Definition  ........................................................................................... 38 
7.13.7.2  Reporting Serious Adverse Events .................................................... 38 
7.13.7.3  Sponsor Monitoring of  Adverse Events  .............................................4 1 
7.13.7.4  DSMB Monitoring of  Adverse Events  ................................................ 42 
7.13.7.5  Data Safety Monitoring Board:  Further  Specifics  ................................ 43 
7.13.8  Post-Study Adverse Events and Serious  Adverse  Events  ....................... 43 
Confidential  4 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12 , 2020 
7.13.9  Treatment -Emergent  Adverse Events  ...................................................... 44 
7.14 Concomitant  Medication Assessments ........................................................... 44 
7.15 Removal of Patients from the Trial or  Study  Drug  ........................................... 44 
7.16 Other  Study  Procedures  .................................................................................. 44 
7.17 Appropriateness  of Measurements  .................................................................  44 
8. STUDY ACTIVITIES .................................................................................................. 45 
8.1 Pre-Treatment Screening Phase (Days - 28 to -1) ............................................. 45 
8.2 Hemodynamic  Screening  ................................................................................. 46 
8.2.1  Intracoronary Infusion Procedure (Day  0) .................................................. 46 
8.2.2  2 Week Visit (Day 14 +/ - 4 days)  Procedures  ......................................... 47 
8.2.3  3 Month Visit (Day 90 +/ - 14 days)  Procedures  ...................................... 48 
8.2.4  6 Month Visit (Day 180 +/ - 14 days)  Procedures ..................................... 48 
8.2.5  12 Month Visit (Day 360 +/ - 30 days)  Procedures  .................................. 48 
8.3 Payments  to Patients  ........................................................................................ 49 
8.4 Early  Termination Procedures  ........................................................................... 49 
9. QUALITY CONTROL  AND ASSURANCE  .................................................................  50 
10. PLANNED STATISTICAL  METHODS  ..................................................................... 51 
10.1 General  Considerations  .................................................................................. 51 
10.2 Analysis  Populations  ....................................................................................... 51 
10.3 Demographics and Baseline Characteristics  ................................................... 52 
10.4 Interim Analysis.  .............................................................................................. 52 
11. ADMINISTRATIVE CONSIDERATIONS  .................................................................  50 
11.1 Investigators and Study  Administrative  Structure  ............................................ 52 
11.2 Institutional Review Board (IRB)  Approval  ...................................................... 52 
11.3 Ethical Conduct of  the Study  ........................................................................... 53 
11.4 Patient Information and Consent  ..................................................................... 53 
11.5 Patient  Confidentiality  ..................................................................................... 54 
11.6 Study  Monitoring ............................................................................................. 54 
11.7 CRFs and Study  Records  ............................................................................... 55 
11.8 Protocol  Violations/Deviations  ......................................................................... 55 
11.9 Access to  Source Documentation ................................................................... 55 
11.10  Data Generation and Analysis  ...................................................................... 55 
Confidential  5 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
 11.11  Retention of Data .......................................................................................... 56 
11.12  Financial  Disclosure  ...................................................................................... 56 
LIST  OF APPENDICES ................................................................................................ 57 
Appendix 1: SCHEDULE OF  STUDY ACTIVITIES/ASSESSMENTS  ............................ 58 
Appendix 2: STUDY RECRUITMENT TIMELINE  .......................................................... 59 
Appendix 3: PROHIBITED CONCOMITANT MEDICATIONS ....................................... 60 
Appendix 4: INFORMED CONSENT  TEMPLATE  ......................................................... 64 
REFERENCES  .............................................................................................................. 65 
Confidential  6 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
 STUDY SYNOPSIS  
Sponsor: Eduardo Marbán, MD, PhD - Cedars-Sinai Heart Institute Investigators: 
Michael R Zile, MD, Sheldon Litwin, MD, Valerian  
Fernandes, MD, Eduardo Marbán, MD, PhD 
 
 
Name of Study Therapy:  
Allogeneic Cardiosphere- Derived Cells -  CAP- 1002  
 
Title of Study:  
 
Regress- HFpEF:  Regression of fibrosis & reversal of diastolic dysfunction  in 
HFpEF  patients treated with allogeneic CDCs  
 
Study Phase: 2 Objectives:  
Primary : To determine the safety profile of CAP -1002 administered by 
intracoronary infusion in patients with Heart Failure and a Preserved Ejection 
Fraction ( HFpEF ). 
 
Secondary: To assess exploratory efficacy endpoints to determine whether 
treatment of HFpEF  patients with intracoronary allogeneic CDCs affects  clinical 
functional  status  (QOL  scores),  exercise  tolerance (6 Minute Walk  Test - 6MWT), 
exercise hemodynamics (supine exer cise ergometry during right heart 
catheterization),  myocardial  interstitial fibrosis  (MRI with native T1 mapping and 
calculation of extracellular volume [ECV] after gadolinium administration), macroscopic fibrosis by delayed gadolinium enhancement (DGE), and diastolic function (catheterization, echocardiography,  BNP).  
 
Study Rationale:  
HFpEF  is a distinct clinical heart failure syndrome and represents a critical unmet 
need in cardiovascular medicine. 1-4 HFpEF  patients have a marked increase in 
morbidity and mortality and a profound clinical disability. 5, 6-13 However, to date, no 
management  strategies have been definitively demonstrated to decrease morbidity 
and mortality or decrease the clinical disability  suffered  by HFpEF  patients.  14-20 We 
postulated that one pivotal  reason that  previous  randomized clinical studies  have 
failed  to show  efficacy in HFpEF  trials centers around the incomplete understanding 
of the pathophysiologic mechanisms underlying the development of HFpEF . 
Studies in patients with HFpEF  and in relevant animal models of HFpEF  have 
demonstrated that one critical mechanism c ontributing to HFpEF  involves changes 
in the cardiac interstitium and extracellular matrix (ECM) fibrillar collagen 
homeostasis. 21,22 
Confidential  7 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
Our pre -clinical studies demonstrated that a highly novel application of cell therapy 
(Allogeneic Cardiosphere- Derived Cells -  CAP- 1002) to a rodent model of HFpEF  
results in regression of ECM fibrosis and reversal of LV diastolic dysfunction 57. 
Thus, use of CDCs in patients with HFpEF  has the potential to significantly reduce 
fibrosis and improve diastolic function.  
 
Study Design:  
 
Patients with HFpEF  meeting all inclusion and no exclusion criteria will be enrolled. 
A randomized, double blind, placebo- controlled (RCT) Phase 2 feasibility study will 
be conducted. This Phase 2 RCT will study a reasonably homogeneous HFpEF  
patient population. The goal is to recruit an enriched sample of patients with 
structural/functional abnormalities like those in the pre-  clinical rat model, with a 
limited number/extent of co -morbid conditions. A randomized, double blind, 
placebo- controlled design in 40 patients with 1: 1 randomization (20 placebo, 20 
CDC treated) will be performed. Patients will be assessed at screening, post -
infusion, 2 weeks, 3, 6, and 12 months after treatment. The effects of one- time 
administration of CDCs in patients with HFpEF  will be examined.  
 
Patient Population:  
Three (Zile, Litwin, Fernandes) of the 4 study investigators have dual appointments  
at the RHJ Department  of Veterans  Administration Medical  Center (VAMC) and 
Medical University of South Carolina Hospital Authority (MUSC). These individuals will be the ones responsible for clinical trial execution, including patient enrollment. Patients referred from either center are screened at MUSC, where all tests, procedures and study visits are performed and which will have sole responsibility for th e conduct of the trial. Screening for enrollment is from three primary sources: 
patients hospitalized for HF, patients in primary and specialty care clinics with HF as a listed problem, and patients undergoing echocardiography with a request listing HF as a problem or a result identifying evidence of increased LV filling pressures. Over the last 6 months, these screening methods have yielded a list of 337 patients that would fulfill the inclusion and exclusion criteria for Regress -HFpEF  
listed below. Our pr evious studies indicate that we have been successful in 
recruiting 54– 69 % of eligible subjects into RCTs and investigator initiated studies. 
Therefore, recruitment expectations are justifiable.  
 Recruitment time- line: 2.0 patients / month, 40 patients by month 20 
(approximately 20 males and 20 females from VAMC or MUSC), 6 month endpoints at month 26, 12 month endpoints at month 32, complete analysis finished by month 36. (See Appendix 2).  
 
Main Criteria for Inclusion/Enrollment:  
 
Confidential  8 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
 
Inclusion Criteria:  
• ≥ 18 years old, male or  female  
• LVEF ≥  50%  
• Symptoms and physical findings of chronic heart failure (NYHA class II - ambulatory  
IV) 
• Treatment with a stable, maximally tolerated dose of diuretic(s) for a minimum of 30 
days prior to randomization.  
• Left atrial (LA) enlargement [ defined by at least one of the following: LA width 
(diameter) ≥ 3.8 cm or LA length ≥ 5.0 cm or LA area ≥ 20 cm2 or LA volume ≥ 55 
mL or LA volume index ≥ 29 mL/m2] or LV concentric remodeling (LV posterior or 
septal wall thickness ≥ 1.2 cm) using echo or MRI   
• BNP > 125 pg/ml  for patients  in NSR or > 150 pg/ml  for patients  in AF or resting 
PCWP > 15 mmHg, or exercise PCWP > 18  mmHg  
• Ability  to provide informed consent  and follow- up with protocol  procedures.  
 
Exclusion Criteria:  
• Any confirmed prior echocardiographic measurement of LVEF < 40 % 
• Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery, 
or percutaneous coronary intervention (PCI) within the 3 months prior to 
randomization or previous CABG or Non-revascularized,  hemodynamically  
significant  CAD (FFR  < 0.75)  
• Current acute decompensated HF 
• Alternative  diagnoses  that in the opinion of the investigator  could account  for the 
patient’s HF symptoms such as severe pulmonary disease (i.e., requiring home 
oxygen, chronic nebulizer therapy, chronic oral steroid therapy);  hemoglobin (Hgb)  
< 10 g/dl; body  mass  index  (BMI)  > 45 kg/m2 
• Use of investigational drugs or treatments at the time of  enrollment  
• Systolic blood pressure > 150 mmHg unless receiving ≥ 3 antihypertensive drugs  
• History  of any dilated  cardiomyopathy;  right sided HF in the absence of left-sided 
structural heart disease; pericardial constriction, genetic hypertrophic 
cardiomyopathy, or infiltrative cardiomyopathy; clinically significant congenital heart  
disease;  hemodynamically  significant  valvular  heart  disease 
• Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within 3  
months  
• Uncontrolled dysrhythmia; symptomatic or sustained ventricular tachycardia or atrial 
fibrillation or flutter with a resting ventricular rate > 110 beats per minute  
• Prior major organ transplant or intent to transplant (i.e., on transplant  list) 
• Hepatic disease as determined by any one of the following: SGOT (AST) or SGPT  
(ALT)  values  exceeding 3x the upper  limit of normal  (ULN),  bilirubin  > 1.5 mg/dl; 
history of chronic viral  hepatitis  
• Chronic Kidney Disease with eGFR < 30 mL/min/1.73 m2; serum potassium  > 5.5 
mmol/L (mEq/L)  
• History  or presence of any other  disease with a life expectancy  of < 3 years  
• Non-compliance to medical  regimens  
• Drug or alcohol abuse within the last 12 months  
• Devices that are MRI incompatible 
Confidential  9 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
• History of malignancy within the past 5  years  
• Pregnant  or nursing (lactating)  women confirmed by a positive  human chorionic 
gonadotropin (hCG); women of child- bearing potential (physiologically capable 
of becoming pregnant), unless using highly effective contraception methods 
during study  
• Diagnosis of active myocarditis  
• Known hypersensitivity to contrast  agents  
• Known hypersensitivity to dimethyl sulfoxide  (DMSO)  
• Known hypersensitivity to bovine products  
• History of heparin induced thrombocytopenia (HIT)  
• Active infectio n not responsive to treatment  
• Active  allergic  reactions or  connective tissue  diseases . 
• History of cardiac tumor or cardiac tumor demonstrated on screening 
• History of previous stem cell  therapy  
• Human Immunodeficiency Virus (HIV)  infection  
OUTCOME MEASURES  
 
Primary Safety endpoints:  
The primary endpoint is the proportion of subjects experiencing any of the following safety -related events during or post intracoronary delivery during the 
six and twelve month follow -up period:  
• TIMI myocardial perfusion grade: New TIMI flow 0 –2 or TIMI my ocardial 
perfusion grade (TMPG)  0–2, noted immediately  following  intracoronary  infusion 
of CAP- 1002 and persisting > 3 min after cell infusion, despite intracoronary 
vasodilator  administration.  
• Acute myocarditis within one month of intracoronary infusion, possibly 
attributable to CAP -1002, diagnosed with consideration of clinical context, with 
or without  a clinically  indicated endomyocardial  biopsy.  In order  to be considered 
related to CAP- 1002,  humoral  or cellular  immune reaction specific  to CAP- 1002 
must also be documented.  
• Ventricular tachycardia or ventricular fibrillation (defined as occurring with ECG 
documentation of these arrhythmias during ambulatory ECG monitoring in an outpatient  setting,  or during routine ECG  monitoring while  hospit alized)  resulting 
in death, or requiring medical intervention, within 72 hours of intracoronary infusion.  
• Sudden unexpected death within 72 hours of intracoronary infusion defined as 
occurring within 1 hour of symptom onset, or unwitnessed death in a person previously  observed to be well within  the preceding 24 hours  without  an identified 
cause.  
• Major  adverse cardiac  events  (MACE)  within  72 hours  of intracoronary  infusion, 
including death,  non-fatal myocardial infarction and re-hospitalization  for 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  10 October 12, 2020   
  
cardiovascular event (including heart failure hospitalizations). Evidence of 
myocardial injury will be assessed by a rule out MI cardiac enzyme protocol performed following  administration  of CAP- 1002 or placebo.  Troponin I and CK- MB 
will be obtained in a serial fashion over 24 hours  after CAP- 1002 infusion.  
 
Secondary Safety endpoints (Short and Long Term):  
• Major adverse cardiac events (MACE), including death, non- fatal myocardial 
infarction, hospitalization for cardiovascular event (including heart failure 
hospitalizations), emergency room treatment for heart failure (including outpatient  
infusion).  
• Any hospitalization due to a cardiovascular  cause or related to CAP- 1002.  
• Any inter-current  cardiovascular  illness  or one related to CAP- 1002.  Evidence  of 
myocardial injury will be assessed by a rule out MI cardiac enzyme protocol, 
troponin I and CKMB  levels.  
• Development of increased DSA levels specific to the CAP -1002 CDC donor at 
immunologically significant  titers.  
 
 
Efficacy Endpoints (Exploratory): 6 - and 12- month follow -up periods*:  
• Absolute and relative  change in myocardial  structure  and function:  measured  by 
echocardiogram,  MRI:  
• LV volume, mass, EF, regional wall motion. Based on rodent data, none of these parameters are expected to change either as a function of time or treatment.  
• Regression of myocardial fibrosis ECV by MRI T1 mapping.  
• Improvement of diastolic dysfunction by echo parameters and reduction in LV filling pressures by catheterization and exercise hemodynamics.  
• Absolute and relative reduction in BNP.  
• Absolute and relative increase of 6MWT Distance  
• Absolute and relative improvement in Quality of Life (QOL) questionnaire 
MLWHF.  
• Absolute and relative reduction in pro- inflammatory and pro- fibrotic signaling 
measured by plasma biomarkers and plasma proteomics.  
* Cath and MRI will only be done at the 6- month time point.  
 
• Transthoracic Echocardiogram : 
 
 Rationale: evaluate indices of LV systolic and diastolic function and LV and left 
atrial structure estimates to characterize any improvement or stability over time with 
the use of  CDCs  
 Indices for  safety:  
EF, LVEDV, regional wall motion  
 Indices for  efficacy:  
E/E’, LA Volume, RV systolic pressure estimates, LV mass  
 
 
• Cardiac MR (with and without contrast):  Unless known  contra- indications  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  11 October 12, 2020   
  
 Rationale: evaluate myocardial interstitial  fibrosis  
 Indices:  
MRI with native  T1 mapping and calculation of extracellular  volume [ECV] 
Macroscopic fibrosis by delayed gadolinium enhancement  (DGE)  
 
• Right Heart  Catheterization:  
 
 Rationale: assess LV diastolic function at rest and during supine bicycle 
ergometry.  
 
 Indices: PCWP, PA systolic and diastolic pressure, cardiac  output  
 
• BNP:  
 
 Rationale: Reflects changes in LV filling pressure using non- invasive method 
 
• 6MWT:  
 
 Rationale: Assess exercise capacity using noninvasive method 
 
• Quality of Life Questionnaire (QOL) : 
 
 Rationale:  to obtain baseline and follow- up evaluation of QOL  spanning key 
domains pertinent to HFpEF  
 
 Tool: Minnesota Living with Heart Failure (MLWHF)  
 
Test Product, Dose, and Mode of Administration:  
Non-occlusive, sequential, three- vessel intracoronary delivery of 25 million CDCs  
(or placebo)  in each of the three coronary  arteries,  as used safely  to date in 14 
subjects in the DYNAMIC trial. This method achieves broad myocardial coverage  
and is atraumatic  to vessel  walls,  as a flexible  guiding catheter  is used to deliver the 
cells. Capricor has extensive experience with manufacturing of CAP -1002 and 
identical -appearing placebo (both provided in amber -colored syringes). 
Transplant -quality donor hearts that coul d not be used clinically are used as the 
starting material for CAP -1002, in a manufacturing process described previously.  
Using SAS or comparable software, the company will provide the master 
randomization list of a 1:1 (CAP -1002 to placebo) randomization using permuted 
blocks with random block sizes of 2 or 4 without stratification. In addition, the company, through its third- party drug depot, will ship investigational product to the 
MUSC research pharmacy on a just in time, per patient basis before each scheduled infusion.  
 
Duration of Treatment : 
All patients will be followed until they have reached 12 months follow -up. 
 
 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  12 October 12, 2020   
 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
 
 
μl Microliter  
AE Adverse Event  
ALB Albumin  
ALK- P Alkaline  phosphatase  
ALT  Alanine aminotransferase (same as SGPT) 
AST Aspartate aminotransferase (same as  SGOT) 
ATM  Atmospheres  
β-HCG   Beta Human Chorionic  Gonadotropin 
BP Blood  Pressure 
BNP Brain natriuretic  peptide 
BUN  Blood urea nitrogen  
C Celsius  
CCU  Critical (or Coronary) Care Unit 
CDC  Cardiosphere Derived Cell 
ceMRI  Contrast -Enhanced Magnetic  Resonance Imaging 
CFR Code of Federal  Regulations  
CHF Congestive Heart  Failure 
CI Cardiac  Index  
CK-MB  Creatine phosphokinase MB isoenzyme 
CMV Cytomegalovirus  
CO Cardiac  output 
CRF Case Report  Form  
CRP  C-reactive protein 
CS Clinically  Significant  
CT Computerized Tomography  
DLCO  Diffusing Capacity for  Carbon Monoxide 
DMSO  Dimethyl Sulfoxide  
DSMB  Data Safety Monitoring Board  
DCE- CMR  Dynamic Contrast Enhanced Cardiac  Magnetic  Resonance 
ECG   Electrocardiogram  
EDV End-Diastolic  Volume  
ESR Erythrocyte Sedimentation Rate  
ESRP  Expedited Safety  Report  
ESV End-Systolic  Volume  
F Fahrenheit  
FDA Food and Drug Administration 
FFR Fractional Flow  Reserve 
GCP Good Clinical  Practice  
Confidential  13  October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12 , 2020 
 
GFR  Glomerular Filtration Rate  
HR Heart  Rate  
HBsAg  Hepatitis B Surface Antigen  
Hct Hematocrit  
HCV  Hepatitis C Virus  
HF Heart  Failure 
Hb Hemoglobin 
HIPAA  Health Insurance Portability and Accountability  Act 
HIV Human Immunodeficiency  Virus  
HLA Human Leukocyte Antigen  
ICF Informed Consent  Form  
ICH International Conference on Harmonization 
IEC Independent Ethics  Committee  
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IND Investigational New  Drug  
INR International Normalized Ratio  
IRB Institutional Review  Board  
K Potassium  
kg Kilogram  
LDH Lactate dehydrogenase 
LV Left Ventricle  
LVEF  Left Ventricular  Ejection  Fraction 
M Million  
MACE  Major Adverse Cardiac  Event  
mcg Microgram  
MCHC  Mean corpuscular  hemoglobin concentration 
MCV Mean corpuscular  volume 
MedDRA  Medical Dictionary for  Regulatory  Activities  
MI Myocardial  Infarction  
min Minute 
mL Milliliter  
mm Millimeters  
mmol  Millimole  
Na Sodium  
NCS   Not clinically  significant  
NYHA  New York  Heart  Association  
p Probability  
PA Pulmonary  Artery  
PBS Phosphate buffered saline  
PCWP  Pulmonary capillary  wedge pressure 
mPAP  Mean pulmonary  artery  pressure 
PRA  Panel Reactive  Antibodies  
PSP Patient Specific  Probability  
PT Prothrombin time 
PTT  Activated partial  thromboplastin time 
r Correlation  coefficient  
RBC  Red blood cell 
Confidential  14  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
October 12, 2020   
  
SAE Serious Adverse Event  
SAP Statistical Analysis  Plan 
SD Standard Deviation  
SE Standard Error  
SVT Supraventricular  Tachycardia 
6MWT Six Minute Walk  Test 
SGOT  Serum Glutamic  Oxaloacetic  Transaminase 
SGPT  Serum Glutamic  Pyruvic Transaminase 
SPRO  Serious Procedure Related Outcome  
TTE Transthoracic  Echocardiography  
UA Urinalysis  
VGEF  Vascular Endothelial  Growth  Factor 
VT Ventricular Tachycardia 
WBC  White Blood  Cell 
Confidential  15  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
October 12, 2020   
  
1.1 Rationale for Study and Patient Population:  
HFpEF  is a distinct clinical heart failure syndrome and represents a critical unmet need 
in cardiovascular medicine. 1-4 HFpEF patients have a marked increase in morbidity and 
mortality and a profound clinical disability. 5, 6- 13 However, to date, no management  
strategies have been definitively demonstrated to decrease morbidity and mortality or 
decrease the clinical disability suffered by HFpEF  patients. 14-20 We have postulated that 
one pivotal reason that previous randomized clinical studies have failed to sh ow efficacy 
in HFpEF trials centers around the incomplete understanding of the pathophysiologic 
mechanisms  underlying the development  of HFpEF . Studies  in patients  with HFpEF  and 
in relevant animal models of HFpEF have demonstrated that one critical mechanism 
contributing to HFpEF are changes in the cardiac interstitium and extracellular matrix 
(ECM)  fibrillar  collagen  homeostasis.  21, 22 Preliminary  studies  presented demonstrate that 
a highly novel application of stem cell therapy to a rodent model of HFpE F results in 
regression of ECM fibrosis and reversal of LV diastolic dysfunction57. These preliminary 
studies form the foundation for this proposed application in HFpEF . 
Health care utilization and costs in HFp EF: HFpEF patients consume an enormous 
percentage of all health care utilization costs. Previous studies and preliminary data 
demonstrate that HFp EF health care utilization costs are driven in part by very high 
hospitalization and repeat hospitalization rates. 1,11,12 Hospitalization for HFp EF exceeds 
15%/year in selected patients in RCTs, 25 %/year in unselected epidemiologic studies, and 25% / year in our preliminary VA data. We reviewed 800 consecutive HF hospitalizations at the Charleston VA site in patients wit h an echocardiogram at the time 
of hospitalization to determine presence of HFpEF, frequency  and costs.  There were  412 
HFpEF admissions, mean age 72 ± 10 (SD) years, length of stay 5 ± 2 (SD) days, total 
inpatient cost $13,322 ± 5,5051 (SD) including bed day, laboratory, radiology, pharmacy and other costs and a frequency of 1.5 ± 0.5 (SD) HF hospitalizations/patient/2 years observation. Once hospitalized for HFp EF, the incidence of re- hospitalization is ~50% in 
6 months and patients require frequent outpat ient visits by primary and specialty care, 
frequent  tele-health care visits,  diagnostic  testing and medications.  In addition,  there is a 
high risk of death with a 5-year mortality  rate ~50%.  The annual  VA cost / HFpEF patient 
is ~$15,000;  based on one five-day hospitalization ($12,500),  four outpatient  visits ($500), 
four medications  ($100/month),  annual  echo,  blood tests,  X-rays ($1,500).  Thus,  HFpEF 
represents an important target for cost and health care utilization reduction.  
Quality of life (QOL) in HFp EF: HFpEF patients have a low QOL with debilitating 
symptoms. This cardiac disability has been objectively assessed by a 6- minute hall walk 
(6-MHW), standard exercise treadmill, and cardiopulmonary exercise testing. 
1,11,12 Our 
studies have demonstrated that serial 6- MHW performed successfully in > 92% of our 
HFpEF patients has very high reproducibility and is significantly reduced (220 m vs 550 
m in age-  and sex -matched controls). 24 Cardiac symptom status can be assessed by 
QOL  tools validated in HFp EF, including New York Heart Association Class (NYHC), 
Quality of Life in Severe Heart Failure Questionnaire (QLSHFQ), the Chronic Heart Failure Questionnaire (CHQ), the Left Ventricular Dysfunction Questionnaire (LVD), and the Minnesota Living with Heart Failure Questionnaire (MLHFQ). MLHFQ has been successfully applied in HFpEF RCTs  and correlates  well with our preliminary  studies.  
8 In 
addition, preliminary studies indicate that overall VA -specific QOL tool (VA SF -12) is 
abnormal i n HFpEF. 
Confidential  16  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
October 12, 2020   
  
 
 
 
1.2. Prior Human Experience with Cardiosphere- Derived Cells:  
CDCs,  CAP- 1002 safe in patients  with HF: CDCs,  the active  ingredient  in CAP- 1002,  are 
known to secrete numerous bioactive elements after myocardial delivery, which act to 
attenuate fibrosis and reduce inflammation. 28-33 One completed and three ongoing clinical  
trials  indicate  that intracoronary  delivery  of CDCs  appears  to be safe:  
1) CADUCEUS (CArdiosphere- Derived aUtologous Stem CElls to reverse ventric Ular 
dySfunction), IND #13930, [STUDY_ID_REMOVED]; first -in-human trial demonstrated preliminary 
safety and efficacy of autologous CDCs in reducing fibrosis post -myocardial infarction 
(MI) in patients with pre- symptomatic HFREF. Once the indirect mechanism of CDC 
action became evident,  34,32 emphasis  shifted to the allogeneic  product  (CAP- 1002).  
2) ALLSTAR (ALLogeneic heart ST em cells to Achieve myocardial R egeneration),  IND 
#15118,  [STUDY_ID_REMOVED];  a randomized,  double- blind,  placebo- controlled Phase 1/2 study 
of the safety and efficacy of intracoronary delivery of CAP -1002 in subjects with an MI 
and pre- symptomatic ischemic HFREF. ALLSTAR did not reveal an increase in adverse 
events. In the completed 14-patient Phase 1 portion, a relatively small, non- clinically 
significant increase in cardiac enzymes of the scale common with any intracoronary 
intervention, the lack of high level immune response to donor cells, and the absence of any immune- related clinical  sequelae support  the safety  of CAP- 1002.  
35 The randomized, 
double- blind multicenter Phase 2 portion of ALLSTAR is currently undergoing final 
analysis. A prespecified 6- month administrative interim analysis demonstrated a low 
probability (futility) of achieving a statistically -significant difference in the 12- month 
primary efficacy endpoint of percent change from baseline in infarct size as a percent of left ventricular mass as measured by cardiac magnetic resonance imaging (MRI). At 6 
months, a near -statistically significant (p=0.05) reduction of mean end- diastolic volume 
as well as a trend of reduction of mean end-systolic volume,  were  seen in the CAP- 1002 
treatment  group.  There was no notable difference between treatment  groups  with respect 
to the change in ejection fraction.  There were  no safety  signals  in the CAP- 1002 treatment 
cohort.  
3) DYNAMIC (Dilated cardiom Yopathy i Ntervention with A llogeneic MyocardI ally- 
regenerative Cells), IND #15418, [STUDY_ID_REMOVED]; Phase 1 study of the safety of CAP - 
1002 in HFREF patients. Phase 1a portion of DYNAMIC has c ompleted enrollment, with 
14 open- label subjects that received CAP -1002. There have been no serious adverse 
events through completed 6- month follow -up.58 This study is particularly relevant as it 
used identical doses of CAP -1002 and follows the same nonocc lusive sequential 
multivessel delivery strategy as this protocol. The randomized, double blind, placebo-  
controlled Phase 1b portion of DYNAMIC has not been initiated.  
4) HOPE- Duchenne (Halt cardi Omyopathy ProgrEssion in Duchenne), IND 16479, 
[STUDY_ID_REMOVED]. Phase 2a study of CAP -1002 delivered as in the DYNAMIC trial (#3 
above) in boys and young men with Duchenne muscular dystrophy and associated 
cardiomyopathy.  This multicenter  randomized study  is presently  enrolling.  All participants 
will be completing  their final follow- up visit in September  2017 with final analysis  planned 
in the fourth quarter of 2017. In a prespecified 6- month interim analysis, there was no 
significant  difference in the incidence of treatment -emergent  adverse events  between  the 
Confidential  17  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
October 12, 2020   
  
CAP- 1002 treatment  group and usual  care control  group.  MRI revealed greater  scar size 
reduction ( -5.02% vs - 0.23%, p=0.09) and increased inferior wall systolic thickening 
(p=0.02) in CAP -1002 subjects vs. controls. A post hoc responder analysis of mid- distal 
performance of the upper limb (PUL) score improved at week six by ≥ 10% in 42% of 
CAP- 1002 patients  compared to none of the usual -care participants  (p=0.045).  
 
2. STUDY  OBJECTIVES  
 
2.1. Primary  Objective 
 
To determine the safety pr ofile of CAP- 1002 administered by intracoronary infusion 
in patients with Heart Failure and a Preserved Ejection Fraction ( HFpEF). 
 
2.2. Secondary  Objective  
 
To assess exploratory efficacy endpoints to determine whether treatment of HFpEF 
patients with intracor onary allogeneic CDCs affects clinical functional status (QOL 
scores), exercise tolerance (6MWT), exercise hemodynamics (supine exercise 
ergometry  during right heart  catheterization),  myocardial  interstitial  fibrosis  (MRI with 
native T1 mapping and calculation of extracellular volume [ECV] after gadolinium administration), macroscopic fibrosis by delayed gadolinium enhancement (DGE), and diastolic function (catheterization, echocardiography,  BNP).  
 
3. STUDY  ENDPOINTS  
 
3.1 Primary  Endpoints : 
 
3.1.1  Primary Safety  Endpoints  
The primary endpoint is the proportion of subjects experiencing any of the following safety -related events during or post intracoronary delivery during the six and twelve 
month follow -up period:  
• TIMI myocardial  perfusion grade:  New TIMI flow 0–2 or TIMI myocardial  perfusion 
grade (TMPG) 0– 2, noted immediately following intracoronary infusion of CAP - 
1002 and persisting > 3 min after cell infusion, despite intracoronary vasodilator administration.  
• Acute  myocarditis  within  one month  of intracoronary  infusion,  possibly  attributable 
to CAP- 1002, diagnosed with consideration of clinical context, with or without a 
clinically indicated endomyocardial biopsy. In order to be considered related to CAP- 1002, humoral or cellular immune reaction specific to CAP- 1002 must also 
be documented.  
Confidential  18  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
October 12, 2020   
  
• Ventricular tachycardia or ventricular fibrillation (defined as occurring with ECG 
documentation of these arrhythmias during ambulatory ECG monitoring in an 
outpatient setting, or during rout ine ECG monitoring while hospitalized) resulting 
in death, or requiring medical intervention, within 72 hours of intracoronary infusion.  
• Sudden unexpected death within 72 hours of intracoronary infusion defined as 
occurring within 1 hour of symptom onset, or unwitnessed death in a person previously observed to be well within the preceding 24 hours without an identified cause.  
• Major adverse cardiac events (MACE) within 72 hours of intracoronary infusion, 
including death, non- fatal myocardial infarction and r e-hospitalization for 
cardiovascular event (including heart failure hospitalizations). Evidence of myocardial injury will be assessed by a rule out MI cardiac enzyme protocol performed following administration of CAP -1002 or placebo. Troponin I and CK - 
MB will be obtained after CAP -1002 infusion.  
 
 
3.1.2  Secondary Safety endpoints (Short and Long Term):  
• Major adverse cardiac events (MACE), including death, non- fatal myocardial 
infarction, hospitalization for cardiovascular event (including heart failure 
hospitalizations or emergency room treatment for heart  failure).  
• Any hospitalization due to a cardiovascular  cause or related to CAP- 1002.  
• Any inter -current cardiovascular illness or one related to CAP -1002. Evidence of 
myocardial injury will be assessed by a rule out MI cardiac enzyme protocol, troponin I and CKMB  levels.  
• Development of increased DSA levels specific to the CAP -1002 CDC donor at 
immunologically significant  titers.  
 
 
3.2 Secondary  Endpoints 
 
3.2.1. Efficacy Endpoints (Exploratory): 6 - and 12- month follow -up periods*:  
• Absolute and relative change in myocardial structure and function: measured by 
echo,  MRI:  
• LV volume, mass, EF, regional wall motion. Based on rodent data, none of 
these parameters are expected to change ei ther as a function of time or 
treatment.  
• Regression of myocardial fibrosis ECV by MRI T1 mapping.  
• Improvement  of diastolic  dysfunction by echo parameters  and reduction in LV filling 
pressures by catheterization and exercise hemodynamics.  
• Absolute and relat ive reduction in BNP.  
• Absolute and relative increase of 6MWT Distance.  
• Absolute and relative  improvement  in Quality  of Life (QOL)  questionnaire,  MLWHF.  
Confidential  19  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
October 12, 2020   
  
• Absolute and relative reduction in pro- inflammatory and pro- fibrotic signaling 
measured by plasma biomarkers and plasma proteomics.  
* Cath and MRI will only be done at the 6- month time point.  
 
4. INVESTIGATIONAL  PLAN 
4.1 Overall Study Design and Plan  
 
Hypothesis:  Treatment  of patients  with symptomatic  hypertensive heart  disease- induced 
HFpEF with allogeneic CDCs will be safe and will improve clinical functional status, 
exercise  tolerance/hemodynamics,  myocardial  interstitial  structure,  and diastolic  function; 
the mechanisms underlying these improvements will be reflected in changes in plasma 
biomarkers  that indicate a reduction in pro-inflammatory  and pro-fibrotic  signaling.  
Specific Aims:  
Perform a randomized, double blind, placebo- controlled Phase 2a feasibility study to 
determine whether treatment of HFp EF patients with intracoronary alloge neic CDCs 
affects clinical functional status (QOL scores), exercise tolerance (6MWT), exercise hemodynamics  (supine exercise  ergometry  during right heart  catheterization),  myocardial 
interstitial fibrosis (MRI with native T1 mapping and calculation of extr acellular volume 
[ECV] after gadolinium administration), macroscopic fibrosis by delayed gadolinium enhancement  (DGE), and diastolic  function (catheterization,  echocardiography,  BNP).  
Determine whether treatment with CDCs affects plasma biomarkers that indicate alterations in proinflammatory and profibrotic mechanisms and whether these biomarker changes  correlate  with alterations  in clinical symptom  status,  myocardial  structure  and/or 
diastolic  function.  
Use these feasibility and exploratory efficacy data study data to 1) confirm that the application of CDCs is safe in HFp EF patients and 2) optimize the design of a Phase 2b 
trial including determination of sample size power  estimates  and appropriate  primar y and 
secondary  endpoints.  
Research Strategy / Clinical Trial Design: This Phase 2a RCT will study a reasonably 
homogeneous HFpEF patient population. The goal is to recruit an enriched sample of 
patients with structural/functional abnormalities like those in the DS rat model  57, with a 
limited number/extent of co- morbid conditions. A randomized, double blind, placebo-  
controlled design in 40 patients  with 1:1 randomization (20 placebo,  20 CDC treated)  will 
be performed. Patients will be assessed at baseline, post -infusion, pre-discharge, 24- 48 
hours post discharge, 0.5, 3, 6, and 12 months after treatment.  
Here we are studying the effects of one- time administration of CDCs in patients with 
HFpEF. While CDCs benefits persist for at least several weeks in the DS rat model, it is 
possible  that benefits  in humans  may wear  off over time. Thus,  one of the objectives  here 
is obtain preliminary indications of the duration of therapeutic benefits over the year of  
follow- up. If benefits are evident initially but wane over time, future clinical studies may 
be designed to include multiple repeated doses.  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  20 October 12, 2020   
  
Team : The clinical study will be conducted by Dr. Zile and colleagues in Charleston, SC. 
Dr Eduardo Marbán will collaborate on study design and analysis. Capricor  Inc., a 
NASDAQ -traded biotechnology  company  (ticker  symbol  CAPR),  has licensed  all relevant 
intellectual property and is conducting the ongoing ALLSTAR, DYNAMIC, and HOPE - 
Duchenne trials. Capricor  will collaborate by providing at -cost investigational product 
(CAP- 1002  or placebo)  produced under  Good Manufacturing Practices  (GMP) standards 
approved for Phase 2 clinical testing, as well as randomization services, and 
immunological  assays performed through its contracted central  immunology  laboratory.  
Pre-Screen: Patients will be referred from either the RHJ Department of Veterans 
Administration Medical Center (VAMC) or the Medical University of South Carolina Hospital Authority (MUSC) and identified from three primary sources: patients hospitalized for HF, patients in primary and specialty care clinics with HF as a listed problem, and patients undergoing echocardiography with a request listing HF as a 
problem or a result identifying evidence of increased LV filling pressures. Over the last 6 
months, these screening methods have yielded a list of 337 patients that would fulfill the 
inclusion and exclusion criteria for Regress -HFpEF listed below. The referred Veterans, 
will be predominantly male, and MUSC will provide the necessary additional female 
patients to reflect the real -world demographic sex distribution of HFpEF. Our previous 
studies indicate that w e have been successful in recruiting 54– 69 % of eligible subjects 
into RCTs and investigator initiated studies. Therefore, recruitment expectations are justifiable.  
Consent  and Screen:  If a patient  fulfills  the inclusion  criteria  of clinical HF, preserved EF, 
increased BNP or increased PCWP,  and increased LA size or concentric LVH  and has 
none of the exclusion criteria (see details  below),  they will be consented and undergo CT 
coronary  angiography (to define the coronary anatomy; CT scan will not be needed if 
patient has had a recent coronary arteriogram or previous CT scan within 1 year  showing 
no significant CAD). If significant CAD is identified  by CT and confirmed  by subsequent  
coronary  arteriography  and FFR,  subjects will be referred to their physician for 
consideration of a revascularization procedure. If such subjects undergo a revascularization procedure, they may be reconsidered and rescreened for the study, minus a repeat CT, af ter a minimum of 3 months post - revascularization.  
The originally approved protocol called for HLA typing and testing for donor -specific 
antibodies (DSAs), and using this information to choose a CAP -1002 master cell bank 
that lacks expression of the relevant antigen(s), if applicable. We now have clinical information from the randomized placebo- controlled ALLSTAR trial of 134 subjects 
treated with CAP -1002, some of whom were cross -matched and others (n=13) of whom 
had no possible cross- match  and so were  treated with cells from randomly  selected CAP-  
1002 master  cell banks.  There was no difference in efficacy  or safety  between the cross-  
matched and non-cross- matched groups,  with a tendency  to larger  therapeutic  responses 
(i.e., greater attenuation of adverse remodeling after myocardial infarction) in the non - 
cross- matched subjects. Accordingly, we made a protocol modification to eliminate the 
cross- matching requirement for investigational product CAP -1002. We will still perform 
HLA typing and measure DSAs  pre and post-treatment  (for documenting de novo immune 
responses if any) but not cross -match cells. We will also eliminate ELISpot testing, as its 
value is theoretical  and there has been no evidence of a clinically  significant  cell-mediated 
immune res ponse in any of the N=95 subjects tested to date.  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  21 October 12, 2020   
  
 
Endpoint  measurement : Prior  to randomization,  the patient  will undergo measurement  of 
all exploratory efficacy endpoints as listed below:  
Echocardiography and MRI: Assess myocardial structure, function, fibrosis using 
previously  published methods;  36, 37-41 interpretation in our imaging  core lab by Dr. Litwin.  
Catheterization and bicycle  ergometry:  Assess hemodynamics  at rest and during exercise 
using previously published methods; 10,42- 46 interpretation in our hemodynamics core lab 
by Dr. Fernandes.  If PCWP  ≥ 20 mmHg  at rest, bicycle ergometry  will not be performed.  
Biomarkers: Blood will be drawn for the assessment of various candidate biomarkers 
indicative  of inflammation (IL1, 6), fibrosis  (Gal-3, sST-2, collagen pro- and telo-peptides), 
ECM homeostasis (MMPs, TIMPs, SPARC, other matricellular proteins/peptides, TGF - 
b), and t -tubule remodeling (BIN -1) from a peripheral vein.  47-50 
Quality of life: Six -minute hall walk, NYHA class, MLWHF questionnaire.  
Randomization: Non -occlusive, sequential, three- vessel intracoronar y delivery of 25 
million  CDCs  (or placebo)  in each of the three coronary  arteries,  as used safely  to date in 
the DYNAMIC trial. This method achieves broad myocardial coverage and is atraumatic 
to vessel walls, as a flexible guiding catheter is used to deli ver the cells. Capricor has 
extensive experience with manufacturing of CAP -1002 and identical -appearing placebo 
(both provided in syringes masked with amber film -covered barrels). Transplant -quality 
donor hearts that could not be used clinically are used as the starting material for CAP - 
1002, in a manufacturing process described previously.23 Using SAS or comparable 
software, the company will provide the master randomization list of a 1:1 (CAP -1002 to 
placebo) randomization using permuted blocks with random block sizes of 2 or 4 without 
stratification. In addition, the company, through its third- party drug depot, will ship 
investigational product to the MUSC research pharmacy on a just in time, per patient 
basis before each scheduled infusion.  
Follow -up: Safety  measurements  will be made immediately  post infusion,  pre-discharge, 
24-48 hours post -discharge at 2 weeks  and at 3, 6, and 12 months after treatment 
(described below). Efficacy measurements and safety measurements will be made at 6 
and 12 months.  
Inclusion criteria:  
1. ≥ 18 years old, male or  female  
2. LVEF ≥  50% 
3. Symptoms and physical findings of chronic heart failure (NYHA class II - ambulatory 
IV) 
4. Treatment with a stable, maximally tolerated dose of diuretic(s) for a minimum of 30 days prior to randomization.  
5. Left atrial (LA) enlargement defined by at least one of the following: LA width 
(diameter)  ≥ 3.8 cm or LA length ≥ 5.0 cm or LA area ≥ 20 cm
2 or LA volume ≥ 55 mL 
or LA volume index ≥ 29 mL/m2 or LV concentric remodeling (LV posterior or septal 
wall thickness ≥ 1.2 cm) using echo or MRI. 
6. BNP > 125 pg/ml for patients in NSR or > 150 pg/ml for patients in AF or resting 
PCWP > 15 mmHg, or exercise PCWP > 18  mmHg  
7. Ability  to provide informed consent  and follow- up with protocol  procedures.  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  22 October 12, 2020   
  
Exclusion criteria -Specific to HFp EF 
1. Any confirmed prior echocardiographic measurement of LVEF < 40 % 
2. Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery, or 
percutaneous coronary intervention (PCI) within the 3 months prior to  randomization 
or previous CABG or Unrevascularized, hemodynamically significant CAD (FFR <  
0.75)  
3. Current acute decompensated HF 
4. Alternative diagnoses that in the opinion of the investigator could account for the patient’s  HF symptoms  (i.e., dyspnea,  fatigue)  such  as severe pulmonary  disease (i.e., 
requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy); 
hemoglobin (Hgb) < 10 g/dl; body mass index (BMI) > 45 kg/m
2 
5. Use of investigational drugs or treatments at the time of  enrollment  
6. Systolic blood pressure > 150 mmHg but  < 180 mmHg unless receiving 3 or more 
antihypertensive drugs  
7. History of any dilated cardiomyopathy; right sided HF in the absence of left -sided 
structural heart disease; Pericardial constriction, genetic hypertrophic 
cardiomyopathy, or infiltrative cardiomyopathy; clinically significant congenital heart disease; hemodynamically significant valvular heart  disease 
8. Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within the 3 months  
9. Uncontrolled dysrhythmia; symptom atic or sustained ventricular tachycardia or atrial 
fibrillation  or flutter  with a resting ventricular  rate > 110 beats  per minute (bpm)  
10. Prior major organ transplant or intent to transplant (i.e., on transplant  list) 
11. Hepatic disease as determined by any one of the following: SGOT (AST) or SGPT (ALT) values exceeding 3x the upper limit of normal (ULN), bilirubin > 1.5 mg/dl; history of chronic viral  hepatitis  
12. Chronic Kidney Disease with eGFR < 30 mL/min/1.73 m
2; serum potassium > 5.5 
mmol/L  (mEq/L)  
13. History  or presence of any other  disease with a life expectancy  of < 3 years  
14. Non-compliance to medical  regimens  
15. Drug or alcohol abuse within the last 12 months  
16. History of malignancy within the past 5 years  
17. Pregnant or nursing (lactating) women confirmed by a positive human chorionic gonadotropin (hCG); women of child- bearing potential (physiologically capable of 
becoming pregnant),  unless  using highly  effective  contraception methods  during study  
18. Devices that are MRI incompatible 
 
Exclusion crite ria-Specific to CAP- 1002 (not listed above)  
1. Diagnosis of active myocarditis  
2. Known hypersensitivity to contrast  agents  
3. Known hypersensitivity to dimethyl sulfoxide  (DMSO)  
4. Known hypersensitivity to bovine products  
5. History of heparin induced thrombocytopenia (HIT)  
6. Active infection not responsive to treatment  
7. Active  allergic  reactions or  connective tissue  diseases  
8. History of cardiac tumor or cardiac tumor demonstrated on screening 
9. History of previous stem cell  therapy  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
Confidential  23 October 12, 2020   
  
10. Human Immunodeficiency Virus (HIV)  infection  
 
Endpoints : The primary  objective is to determine the safety  of CAP- 1002 administered by 
multi -vessel, non- occlusive intracoronary infusion in subjects with HFp EF. A secondary 
objective is to explore, in a non- hierarchical manner, efficacy end- points that will be of 
value intrinsically as indicators of bioactivity as well as in guiding future trials with CAP - 
1002.  
Safety endpoints : The primary endpoint is the proportion of subjects experiencing any of 
the follow ing safety -related events  during or post intracoronary  delivery  during the six and 
twelve month follow -up period:  
1. New TIMI flow 0 –2 or TIMI myocardial perfusion grade (TMPG) 0– 2, noted 
immediately  following  intracoronary  infusion of CAP- 1002 and persisting > 3 min after 
cell infusion,  despite intracoronary  vasodilator  administration.  
2. Acute myocarditis within one month of intracoronary infusion, possibly attributable to 
CAP- 1002,  diagnosed  with consideration of clinical context,  with or without  a clinically 
indicated endomyocardial biopsy. In order to be considered related to CAP -1002, 
humoral  or cellular  immune reaction specific  to CAP- 1002 must  also be documented.  
3. Ventricular tachycardia or ventricular fibrillation (defined as occurring with ECG documentation of these arrhythmias during ambulatory ECG monitoring in an outpatient setting, or during routine ECG monitoring while hospitalized) resulting in death,  or requiring medical  intervention,  within  72 hours  of intracoronary  infusion.  
4. Sudden unexpected death within 72 hours of intracoronary infusion defined as 
occurring within  1 hour of symptom  onset,  or unwitnessed  death in a person previously 
observed to be well within the preceding 24 hours without an identified cause.  
5. Major adverse cardiac  events (MACE) within 72 hours of intracoronary infusion, 
including death, non- fatal myocardial infarction and re- hospitalization for 
cardiovascular  event  (including  heart  failure  hospitalizations).  Evidence  of myocardial 
injury will be assessed by a rule out MI cardiac enzyme protocol performed following administration of CAP -1002 or placebo. Troponin I and CK -MB will be obtained after 
CAP- 1002 infusion.  
 
Secondary safety endpoints:  
1. Major adverse cardiac events (MACE), including death, non- fatal myocardial 
infarction, hospitalization for cardiovascular event (including heart failure hospitalizations and emergency room treatment for heart  failure).  
2. Any hospitalization due to a cardiovascular  cause or related to CAP- 1002.  
3. Any inter -current  cardiovascular illness or one related to CAP -1002. Evidence of 
myocardial  injury  will be assessed  by a rule out MI cardiac  enzyme protocol,  troponin 
I and CKMB  levels.  
4. Development of increased DSA levels specific to the CAP -1002 CDC donor at 
immunological ly significant  titers.  
Confidential  24  October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
Efficacy endpoints (exploratory): 6- and 12- month follow -up periods*:  
1. Absolute & relative  change in myocardial  structure  & function:  measured by echo, MRI:  
a) LV volume, mass, EF, regional wall motion. Based on rodent data, none of these 
parameters are expected to change either as a function of time or  treatment.  
b) Regression of myocardial fibrosis ECV by MRI T1 mapping.  
c) Improvement  of diastolic  dysfunction by echo parameters  and reduction in LV filling 
pressures by cath and exercise hemodynamics.  
2. Absolute and relative reduction in BNP.  
3. Absolute and relative increase of 6MWT distance.  
4. Absolute and relative  improvement  in Quality  of Life (QOL)  questionnaires  VA SF-12, 
MLWHF.  
5. Reduction in pro- inflammatory and pro- fibrotic  signaling.  
* Cath and MRI will only be done at the 6- month time point.  
Statistical analysis : An independent DSMB, with roles and responsibilities defined in a 
written  charter,  was appointed to oversee safety  of the study.  The DSMB will consist  of 
three heart failure cardiologist s, one with additional expertise in interventional cardiology, 
one with additional expertise in imaging, one with additional expertise in transplant/immunology , and a statistician. The DSMB may request additional interim 
analyses and develop other criteria for determining when to intervene in the enrollment  
or treatment of subjects  in the study.  Monitoring of all safety  endpoints  will be conducted. 
Individual cases reported to regulatory bodies will be reported to the DSMB Chair  and will 
be reviewed  by the DSMB.  The DSMB will have access to reports evaluating group trends 
for CAP- 1002 vs. Control as well as data from the literature for CAP -1002- treated 
subjects. In addition, any external concerns regarding CDC safety will be brought to the attention of the DSMB.  
The proportion of subjects experiencing an adverse event or a protocol -specific safety 
event (PSE)  will be monitored at pre- planned intervals set by the DSMB. A futility chart 
will be created to allow  for DSMB safety  monitoring.  The excess for CAP- treated subjects 
is of primary concern as Phase 2a data accrue. The boundaries are computed using StatXact  v7 (CyTel, Cambridge MA); a one- sided 95% exact test is performed assuming 
binomially distributed outcomes. The chart will be applied to any binary outcome 
pertaining to safety. The chart will be computed over a broad range of possible PSE 
outcomes. No adjustment for Type I error will be made for repeated looks since the ultimate decision regarding safety represents a clinical decision involving all safety endpoints  in the context  of efficacy.  Descriptive  summaries  will be provided for all primary 
and secondary endpoints for both safety and efficacy. A prospective statistical analysis plan (SAP) will be generated for DSMB review with their input. All analyses and reports will be developed per Good Clinical Practices. All analyses will be performed using SAS  
Version 9.2 or  greater.  
Efficacy data will be presented as mean changes from screening at designated visits. These Phase  2a data will be used  to calculate effect  sizes  for planning subsequent  Phase 
2b studies.  If there  are sufficient  follow- up data,  longitudinal  models  (SAS PROC MIXED 
for continuous endpoints and SAS PROC GENMOD for binary endpoints) will be explored. A formal SAP will be developed in a collaboration between Dr. Zile, MUSC statistician Dulaney Wilson (in the Department of Public Healt h Sciences),  CSMC and 
Capricor . Dr. Wilson , Professor,  MUSC Department  of 
Confidential  25 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12 , 2020 
 
Public Health Sciences, and the PI/PD Dr. Zile have collaborated on development of 
SAPs for a number of published studies.  
 
4.2 Study Duration and Dates  
Recruitment time line : 2.0 patients / month, 40 patients by month 20 (approximately 20 
males and 20 females  from the VAMC and MUSC), 6 month endpoints at month 26, 12 
month endpoints  at month 32, complete analysis  finished  by month  36. (See  Appendix  2) 
Covid -19 pandemic and FDA review postponed completion of recruitment and 
established new time line.  
 
5. STUDY POPULATION  SELECTION 
5.1 Study Population  
Research Strategy / Clinical Trial Design: This Phase 2a RCT will study a reasonably homogeneous HFp EF patient  population. The goal is to recruit an 
enriched sample of patients with structural/functional abnormalities like those in 
the DS rat model
57, with a limited number/extent of co- morbid conditions. A 
randomized, double blind, placebo- controlled design in 40 patients with 1:1 
randomization (20 placebo, 20 CDC treated) will be performed. Patients will be 
assessed at screening, post infusion, pre- discharge, 24- 48 hrs post -discharge, 0.5, 
3, 6, and 12 months after treatment.  
 
Here we are studying the effects of one- time administration of CDCs in patients 
with HFpEF. It is possible that benefits in humans may wear off over time. Thus, 
one of the objectives here is obtain preliminary indications of the duration of therapeutic benefits over the year of follow -up. If benefits are evident initially but 
wane over time, future clinical studies may be designed to include multiple repeated doses.  
 
Team: The clinical study will be conducted by Dr. Zile and colleagues in 
Charleston,  SC. Dr. Eduardo Marbán will collaborate on study  design  and analysis. 
Capricor  Inc., a NASDAQ -traded biotechnology  company  (ticker  symbol  CAPR),  is 
conducting the ongoing ALLSTAR, DYNAMIC, and HOPE -Duchenne trials. 
Capricor  will collaborate by providing at-cost investigational  product  (CAP- 1002 or 
placebo) produced under Good Manufacturing Practices (GMP) standards 
approved for Phase 2 clinical testing, as well as randomization schedule, and 
immunological assays through a third- party  vendor.  
 
Consent and Screen: If a patient fulfills the inclusion criteria and has none of the 
exclusion criteria (see details below), they will be consented and undergo CT coronary angiography (to define the coronary anatomy; CT scan will not be needed if patient has had a recent coronary arteriogram within 3 months showing no significant CAD) and donor -specific antibodies (DSA). If significant CAD  is 
identified  by CT and confirmed by subsequent  coronary  arteriography  and FFR, the 
patient will be referred to their physician for consideration of a 
Confidential  26 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
revascularization procedure. After a minimum of 3 months following such a 
revascularization procedure, the patient can be reconsidered and rescreened for the study, minus a r epeat CT.  
The originally  approved protocol  called  for HLA typing  and measurement  of donor - 
specific antibodies (DSAs), and using this information to choose a CAP -1002 master  
cell bank  that lacks expression of the relevant  antigen(s),  if applicable.  We now have 
clinical information from the randomized placebo- controlled ALLSTAR trial of 134 
subjects treated with CAP -1002, some of whom were cross -matched and others  
(n=13)  of whom  had no possible cross- match  so were  treated with cells from r andomly 
selected CAP -1002 master cell banks. There was no difference in efficacy  or safety  
between the cross- matched and non-cross- matched groups,  with a tendency to larger 
therapeutic responses (i.e., greater attenuation of adverse remodeling after 
myocar dial infarction) in the non- cross- matched subjects. Accordingly, we made a 
protocol modification to eliminate the cross -matching requirement  for investigational  
product  CAP- 1002.  We will still perform HLA typing and measure DSAs pre and post -
treatment (for documenting de novo immune responses  if any) but not cross -match  
cells.  We will also eliminate  ELISpot  testing, as  its value is theoretical  and there  has 
been no evidence of a clinically  significant cell- mediated immune response in any of 
the N=95 subjects tested to date.  
 
5.2 Inclusion Criteria  
Inclusion criteria:  
Inclusion criteria:  
1. ≥ 18 years old, male or  female  
2. LVEF ≥  50% 
3. Symptoms and physical findings of chronic heart failure (NYHA class II - ambulatory 
IV) 
4. Treatment with a stable, maximally tolerated dose of diuretic(s) for a minimum of 30 
days prior to randomization.  
5. Left atrial (LA) enlargement defined by at least one of the following: LA width 
(diameter)  ≥ 3.8 cm or LA length ≥ 5.0 cm or LA area ≥ 20 cm2 or LA volume ≥ 55 
mL or LA volume index ≥ 29 mL/m2 or LV concentric remodeling (LV posterior or 
septal wall thickness ≥ 1.2 cm) using echo or MRI.  
6. BNP > 125 pg/ml for patients in NSR or > 150 pg/ml for patients in AF or resting 
PCWP > 15 mmHg, or exercise PCWP >  18 mmHg.  
7. Ability  to provide informed consent  and follow- up with protocol  procedures.  
5.3 Exclusion Criteria  
Exclusion criteria -Specific to HFp EF 
1. Any prior echocardiographic measurement of LVEF < 40 % 
2. Acute coronary syndrome (including MI), cardiac surgery, other major CV 
surgery, or percutaneous coronary intervention (PCI) within the 3 months prior to 
randomization or previous CABG or Unrevascularized, hemodynamically significant CAD (FFR < 0.75)  
3. Curre nt acute decompensated HF 
4. Alternative diagnoses that in the opinion of the investigator could account for 
the patient’s HF symptoms (i.e., dyspnea, fatigue) such as severe pulmonary disease (i.e., requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy); 
Confidential  27 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
 hemoglobin (Hgb) < 10 g/dl; body mass index (BMI) > 45 kg/m2  
5. Use of investigational drugs or treatments at the time of  enrollment  
6. Systolic blood pressure > 150 mmHg but < 180 mmHg unless receiving 3 or 
more antihypertensive  drugs  
7. History  of any dilated  cardiomyopathy;  right sided HF in the absence of left- 
sided structural heart disease; Pericardial constriction, genetic hypertrophic 
cardiomyopathy, or infiltrative cardiomyopathy; clinically significant congenital heart  
disease;  hemodynamically  significant  valvular  heart  disease 
8. Stroke, transient ischemic attack, carotid surgery or carotid angioplasty within 
the 3 months  
9. Uncontrolled dysrhythmia; symptomatic or sustained ventricular tachycardi a or 
atrial fibrillation or flutter with a resting ventricular rate > 110 beats per minute (bpm)  
10. Prior major organ transplant or intent to transplant (i.e., on transplant  list) 
11. Hepatic  disease as determined by any one of the following:  SGOT  (AST)  or 
SGPT ( ALT) values exceeding 3x the upper limit of normal (ULN), bilirubin > 1.5 mg/dl; 
history of chronic viral  hepatitis  
12. Chronic  Kidney  Disease  with eGFR  < 30 mL/min/1.73 m2; serum  potassium  
> 5.5 mmol/L (mEq/L)  
13. History  or presence of any other  disease with a life expectancy  of < 3 years  
14. Non-compliance to medical  regimens  
15. Drug or alcohol abuse within the last 12 months  
16. History of malignancy within the past 5 years  
17. Pregnant or nursing (lactating) women confirmed by a positive human chorionic 
gonadotropin (hCG); women of child- bearing potential (physiologically capable of 
becoming pregnant), unless using highly effective contraception methods during study  
18. Devices that are MRI incompatible 
 
Exclusion criteria -Specific to CAP- 1002 (not listed above)  
1. Diagnosis of active myocarditis  
2. Known hypersensitivity to contrast agents or previous H/O  HIT 
3. Known hypersensitivity to dimethyl sulfoxide  (DMSO)  
4. Known hypers ensitivity to bovine products  
5. History of heparin induced thrombocytopenia (HIT)  
6. Active infect ion not responsive to treatment  
7.  Active allergic reactions or  connective tissue diseases  
8.  History of cardiac tumor or cardiac tumor demonstrated on screening 
9.  History of previous stem cell  therapy  
10.  Human Immunodeficiency Virus (HIV)  infection  
 
Endpoints: The primary objective is to determine the safety of CAP -1002 administered  
by multi -vessel,  non-occlusive  intracoronary  infusion  in subjects  with HFpEF. A 
secondary  objective is to explore,  in a non-hierarchical  manner,  efficacy end- points  that 
will be of value intrinsically  as indicators  of bioactivity  as well as in guiding future trials 
with CAP- 1002.   
  
 
 
 
 
Confidential  28 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
 6. STUDY  TREATMENT(S)  
 
6.1 Description of  Treatment(s)  
 
6.1.1 Study Drug  
 
CAP- 1002 CDCs will be grown from an unrelated donor and manufactured by 
Capricor Inc. CAP- 1002 is delivered in a ready -to-use format. CDCs are grown in 
media that contains bovine products, are washed prior to formulation such that 
only trace  amounts  remain (<0.001%),  but patients  with known hypersensitivity  are 
excluded. Each dose of 25 million cells (CAP -1002) or placebo for delivery to the 
patient will be in a final volume of 11.1 mL of cryogenic cell preservation solution 
(CryoStor® CS10, BioLife Solutio ns, Inc.) with 10% dimethyl sulfoxide (DMSO), 
heparin (1800 U) and nitroglycerin (450 mcg). A 12-mL normal  saline and heparin 
(1200 U) wash solution, with or without nitroglycerin (800 mcg), is used to wash 
the lumen of the catheter before and after infusion of CAP -1002 or placebo. The 
wash solution with nitroglycerin is the preferred wash solution; however, a wash 
solution without  nitroglycerin is also prepared for patients  who may be intolerant  to 
nitroglycerin during the infusion procedure. Capricor, the manufacturer of CAP - 
1002 and placebo,  will provide detailed instructions  for the preparation of the saline 
wash solutions and investigational product (CAP -1002 or placebo). The 
investigational pharmacy will prepare the wash solutions in 20 mL barrel syringes 
and each of the three doses of investigational product in 12 mL barrel coronary 
control syringes with amber masking tape around the barrel. The investigational 
pharmacist should maintain sterility of the outside of the syringes so they can be 
dropped onto the sterile  field in the cardiac  catheterization laboratory.  
 
6.2 Treatment  Administered 
 
All patients will have CAP- 1002 or placebo delivered through a coronary catheter 
inserted in the right and left coronary  arteries  using standard techniques  in the cardiac 
catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-  
infusion)  hemodynamics.  Standard diagnostic  angiography  will be performed  prior to 
infusion of the investigational  product  to confirm  patency  of the coronary  arteries  and 
final determination of whether the patient is suitability to undergo the investigational 
procedure.  All patients will receive 25 million cells (CAP -1002) or placebo in each of 
the 3 coronary arteries. Prior to infusion of the investigational product, the lumen of 
the catheter  is flushed with saline -heparin wash  solution (with  or without  nitroglycerin 
depending on individual patient tolerance) for approximately 30 seconds (±5 
seconds).  Sequential  dose administration of 25 million  cells or placebo,  as described 
above, will be infused over 10 minutes (±30 seconds) via a TERUMO FinecrossTM 
MG guiding catheter, the only catheter that has undergone biocompatibility testing 
with CAP- 1002. Following the infusion of the investigat ional product, any residual 
investigational product within the lumen is flushed with saline- heparin wash solution 
(with  or without  nitroglycerin)  for approximately  30 seconds  (±5 seconds).  Patency  of 
the vessel  and TIMI grade 3 flow should be confirmed before  moving  to the next 
Confidential  29 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
vessel; allow at least a five- minute interval between each infusion of investigational 
product while remaining mindful of the labeled expiry time of the investigational 
product. All procedures will be performed by the cardiac interventionist (Dr 
Fernandes).  The patient  will receive local anesthesia +/- gentle  conscious  sedati on if 
undue anxiety.  During  and in between infusions,  multiple  measures  of O2 sat , 
hemodynamics, including blood pressure and heart rate and monitoring for any 
arrhythmias (ventricular and supra- ventricular). Fluids are permitted for hypotension 
during the procedure, as are low dose inotropes such as dobutamine and use of 
inhaled nitric oxide. VPCs or NSVT can be seen with insertion of the PA catheter as it traverses the RV and is easily remedied by catheter withdrawal. Oxygen will be used if needed to treat temporary hypoxia should this occur. If significant adverse events occur, the infusion will be terminated (see details below) . 
 
6.3 Selection and Timing of  Dose  
 
This Phase 2 cohort will include 40 patients randomized in a double- blind fashion to 
receive either CAP -1002 or placebo in a 1:1 ratio. CAP -1002 will be grown from 
unrelated donors. After completion of the screening and baseline procedures, patients will r eceive either CAP -1002 or placebo Infusions within 3 weeks of 
screening and completion of any outstanding baseline studies required to confirm a diagnosis of HFp EF. All patients (those who have undergone CAP -1002 or placebo 
infusion) will be followed until  the last enrolled patient has reached 12- month follow - 
up. Patients  will be followed  post infusion, pre- discharge, 24- 48 hrs post -discharge, at 
week  2 and at months  3, 6, and 12 after CAP- 1002 or placebo infusion.  
 
6.4 Method of Assigning Patients to Treatment  Groups 
 
Randomization: Non- occlusive, sequential, three- vessel intracoronary delivery of 25 
million CDCs (or placebo) in each of the three coronary arteries, as used safely to 
date in the DYNAMIC trial. This method achieves broad myocardial cover age and is 
atraumatic to vessel walls, as a flexible guiding catheter is used to deliver the cells. 
Capricor has extensive experience with manufacturing of CAP -1002 and identical - 
appearing placebo (both provided in amber -colored syringes). Transplant -quality 
donor hearts that could not be used clinically are used as the starting material for 
CAP- 1002, in a manufacturing process described previously.23 Using SAS or 
comparable software, Capricor  will prepare the master randomization list of a 1:1 
(CAP- 1002 t o placebo) randomization using permuted blocks with random block 
sizes of 2 or 4 without stratification. Following randomization, Capricor , through its 
third-party drug depot vendor, will ship out investigational product (CAP -1002 or 
placebo)  on a just in time, per patient  basis  to the MUSC Center  for Cellular  Therapy.  
 
6.5 Concomitant  Therapy 
Concomitant therapies are defined as all therapies received on or after the day of infusion. Those received before the day of infusion are considered prior therapies. Prior therapies will be recorded during initial screening. Concomitant therapies with HFpEF –specific agents will be recorded at each study visit, beginning with the day  
Confidential  30 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12 , 2020  
of infusion,  as well as all other  medications.  All patients  with HFpEF will be on stable 
background diuretic therapy prior to enrollment as well as any adjunctive therapies 
for HFpEF deemed to be necessary in that particular  patient.  
 
6.6 Restrictions 
 
6.6.1  Prior  Therapy 
Patients  who have had previous  stem  cell therapy  or any organ transplant  may not 
participate in this study.  There  are no medication restrictions  except  those listed  in 
Appendix  3. Individual  patient  medication will be advised  by the patient’s  physician 
according to the usual practice of the study site. Coumadin / other anticoagulant discontinuation prior to catheterization will be managed according to standard of care practices.  
 
6.6.2  Fluid and Food Intake 
There are no fluid or food intake restrictions. Patients should follow the diet and 
fluid in take prescribed by their physician.  
 
6.6.3  Patient Activity Restriction 
Patients should follow the activity recommendations prescribed by their physician.  
 
 
6.7 Treatment  Compliance 
 
Since the treatment is a one- time procedure, dosing compliance is not a concern. 
Study  site personnel  will document  compliance with medications  and study  follow- up 
procedures at each study  visit. 
 
 
6.8 Packaging and Labeling 
 
CAP- 1002 will be formulated and frozen in labeled cryogenic bags with 510K 
approval  for the use in protecting,  storing and freezing cells and tissues.  A cryogenic 
overwrap bag will be used to protect the cell storage bag and label during freezing. A 
secondary label will be attached to the cryogenic overwrap bag for quick 
identification. The frozen product will be delivered overnight from Capricor’s third-  
party  drug depot  vendor  to the clinical trial site via a liquid  nitrogen dry vapor  shipper 
(dewar).  The frozen product  will remain in the shipper  (dewar)  until ready  for use. 
 
6.9 Storage and Accountability 
 
The frozen product will only be dispensed once a patient has (1) provided written 
informed consent, (2) met all eligibility criteria for entry into the study, and (3) 
completed all baseline  evaluations.  Detailed  instructions  for storage and handling will 
be provided by Capricor. Once removed from shipper (dewar), Investigators are 
instructed to store the study agent at room temperature (~25oC), and to   administer  
Confidential  31 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12 , 2020  
the study  agent  within  2 hours  of removal  from storage.  The study  site is responsible 
for study  agent  accountability,  reconciliation,  and record maintenance.  In accordance 
with all applicable regulatory requirements, designated study center personnel must 
maintain accountability records throughout the study.  
 
6.10 Investigational Product Retention at Study Site 
 
Since product will be delivered as needed on a per patient basis, there will be no 
product  to retain at the site. The site will be instructed  to retain labels  and packaging 
materials - as part of the patient records. Should a patient be found unsuitable or 
ineligible for infusion after a pr oduct has been delivered to the CVIC, a Quality 
representative at Capricor will provide direction on how to return the investigational 
product.  
 
7. STUDY  PROCEDURES  
 
7.1. Informed Consent  
 
Before being admitted to the clinical study, all patients must consent in w riting to 
participate. An Informed Consent Form (ICF) will be given to each patient, which will 
contain all United  States  federally  required elements,  all ICH-required elements,  and 
Health  Insurance Portability  and Accountability  Act (HIPAA)  authorization information 
in language that is understandable to the patient. The process of obtaining the informed consent will be in compliance with all federal regulations, International Conference on Harmonization (ICH) requirements, and local laws. The Investigator 
will review the study with each patient. The review will include the nature, scope, procedures, and possible consequences of the patient's participation in the study. The ICF and review will be in a form understandable to the patient. The Inv estigator 
or designee and the patient  must  both sign and date the ICF after review  and before 
the patient can participate in the study. The patient will receive a copy of the signed and dated form, and the original  will be retained in the site study  files. The Investigator 
or his/her designee will emphasize to the patient that study participation is entirely voluntary and that consent regarding study participation may be withdrawn at any time without  penalty  or loss of benefits  to which  the patient  is otherwise entitled.  If the 
ICF is amended during the study,  the Investigator  must  follow all applicable  regulatory 
requirements pertaining to approval of the amended ICF by the IRB/IEC. The site must use the amended consent form for all new patients and repeat the consent process with the amended ICF for any ongoing patients.  
 
7.2. Medical  History 
 
A complete medical history, including all elements pertinent to HFp EF (e.g., effort 
intolerance, NYHA FC, exercise– induced chest pain or dizziness/syncope, edema, 
etc., medications,  etc.) of patients  enrolled in the study  will be documented as part of 
the screening process  and reviewed prior to enrollment  into the study.  At subsequent 
visits  (day of infusion  forward),  medications,  general  health and cardiopulmonary  
Confidential  32 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
health will be reviewed including  all elements  pertinent  to HFpEF at each patient  visit 
and new information will be updated in the patient’s  study  documentation.  
 
7.3. Physical  Examination 
 
A qualified physician, either the Principal Investigator or Sub- Investigators will 
perform a comprehensive physical examination aimed at examining all signs 
pertinent to HFp EF at each study visit.  
 
7.4. Vital Signs 
 
Temperature, heart rate, blood pressure, respiration rate, and body weight will be recorded at each visit on the case report form (CRF).  
 
7.4.1.  Laboratory Parameters  
Subjects will be in a seated or supine position during blood collection. Clinical laboratory tests will include the following:  
 
List of laboratory tests 
 
Hematology:  
CBC with differential 
 
Immunology: 
HLA/DSA  
 
Urine Pregnancy Test (for women of 
childbearing potential  
 
Biomarkers HIV Hepatitis panel  Serum Chemistry:  
Albumin (ALB)  
Alkaline phosphatase (ALK -P) 
Alanine aminotransferase (ALT; 
SGPT)  
Aspartate aminotransferase (AST; 
SGOT)  
Blood urea nitrogen (BUN) 
Brain natriuretic peptide (BNP) 
Creatinine  
Creatine kinase and subtypes 
Glucose  
Lactate dehydrogenase (LDH) 
Potassium (K)  
Sodium (Na) 
Total bilirubin 
Direct bilirubin 
Total protein 
Troponin I (baseline and as needed)  
 
Coagulation:  
 
Prothrombin time (PT)  
Activated partial thromboplastin time 
(PTT)  
International Normalized Ratio (INR)  
Confidential  33 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
7.5 12-Lead ECG  
 
Beginning at the screening period, a 12 lead ECG will be performed and then post 
infusion, day of discharge from the hospital, day14, and months 3, 6 and 12. The purpose will be to assess any change in axis, look for new features of LVH, MI, and assess rhythm.  
 
7.6 Echocardiography  
 
An echocardiogram  will be performed during the screening period as well as at months 
6 and 12 visits.  Echocardiography  will be performed to measure LV structure,  systolic 
and diastolic  function.  
 
7.7 Holter Monitor (24 Hour  ECG)  
 
The 24- hour ECG (Holter) will be performed during the screening phase, 0.5, and 6 
months after Cap- 1002 to rule out the presence of significant arrhythmias or 
conduction defects.  
 
7.8 Six Minute Walk  Test 
 
The 6MWT will be performed  at screening and at 6 and 12-month follow- up visit. While 
we will be looking for an improvement  in 6MWT distance,  a ≥ 15% reduction in 6MWT 
distance from baseline will be consider a significant  decline.  
 
7.9 Magnetic Resonance Imaging Protocol  
 
With the exception of those patients with a known contra- indication for MRI, all 
patients will undergo contrast -enhanced magnetic resonance imaging (ceMRI) at 
screening and at month 6. The imaging protocol will first include sagittal, axial and 
oblique scout images to localize the heart. It is anticipated that the duration of each MRI session will be 45 -60 minutes. Acquisition parameters and techniques will be 
protocoled such that ther e is standardization regarding acquisition of the studies. 
Specific measures of note will include LV structure and function. Delayed contrast enhancement can also reflect the presence of myocardial fibrosis. This will not be required in patients in whom there are contraindicated to undergo an MRI.  
 
7.10 Image Analysis 
 
The imaging data will be read by cardiovascular imaging expert: Sheldon Litwin, MD.  
 
7.11 Cardiac CT 
 
A computerized tomography (CT) of the chest and heart will  be performed at the 
screening visit to ensure that there are no clinically  significant pre- existing  
abnormalities particularly calcification, atherosclerosis in the coronary arteries. The CT will be performed with (provided no renal  dysfunction)  and witho ut contrast.  If any 
Confidential  34 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
 abnormalities are found that affect the patient’s participation in the study, the patient 
will be withdrawn from the study as a screen failure and not followed further. The patient must continue to meet all inclusion and no exclusion cr iteria in order to 
continue in the study
 
 
7.12 Clinical Functional Capacity and Quality of Life Measures  
 
New York Heart Association (NYHA) functional status will be evaluated at screening , 
0.5, 3, 6 months, 12 months. A MLWHF QOL questionnaire will be completed at baseline, 6 months and 12 months.  
 
7.13 Adverse Events 
 
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject associated with the use of a medicinal product, whether or not considered related to the medicinal product. The occurrence does not necessarily have to have a causal relationship with the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease (new or exacerbated) temporally associated with the use of a medi cinal product, whether or not considered related to the medicinal 
product.  
 
 
Examples of an AE include:  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency or intensity of the condition.  
• Significant or unexpected worsening or exacerbation of the condition/indication under study.  
• A new condition detected or diagnosed after study therapy administration even though it may have been present prior to the start of the study.  
• Pre- or post -treatme nt events that occur as a result of protocol -mandated 
procedures (e.g., invasive protocol -defined procedures, modification of a patient’s 
previous treatment  regimen).  
 
 
An AE does not include:  
• Medical or surgical procedures (e.g., colonoscopy, biopsy). The medical condition 
that leads to the procedure is an AE. 
• Social or convenience  hospital  admissions  where an untoward medical  occurrence 
did not  occur.  
• Day to day fluctuations of pre- existing disease or conditions present or detected at 
the start of the study that do not  worsen.  
• The disease/disorder being studied or expected progression, signs, or symptoms 
of the disease/disorder being studied unless more severe than expected for the patient’s  condition.  
Confidential  35 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
 
The Investigator will review all documentation (e.g., hospital progress notes, 
laboratory,  or diagnostic  reports)  relative  to the event  being reported.  The Investigator 
or his/her  designee will then record all relevant  information regarding an AE/SAE into 
the CRF.  It is not acceptable for the Investigator  to send photocopies  of the patients’ 
medical records in lieu of completion of the appropriate AE/SAE pages. However, there may be instances when the DSMB Chair requests copies of medical records for certain cases. In this instance, all patient identifiers will be blinded on the copies of the medical records prior to submission to the DSMB  Chair.  
 
The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs and symptoms.  
 
7.13.1 Timing  
 
Adverse event assessment and documentation will occur at each study visit from during and immediately after infusion and then throughout the study. On the day of treatment administration, a patient’s medical complaint will be considered to be a treatment -emergent  adverse event  if the event  occurs  any time after the infusion 
of CAP- 1002 or  placebo.  
 
7.13.2 Severity 
 
The Investigator will make an assessment of  intensity for each AE and SAE 
reported during the study. The assessment will be based on the Investigator’s clinical judgment. The intensity of each AE and SAE will be assigned to one of the following categories:  
 
Mild: An event  that is easily  tolerated by the patient,  causing minimal 
discomfort and not interfering with everyday  activities.  
Moderate: An event that is sufficiently discomforting to interfere with normal 
everyday activities.  
Severe:  An event that prevents normal everyday  activities.  
 
An AE that is assessed as severe will not be confused with an SAE. Severity is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe. An event is described as ‘serious’ when it meets one of the pre- defined outcomes as described in the Section 7.13.7.1, Serious Adverse 
Events.  
 
7.13.3 Relationship 
 
The Investigator  is obligated to assess the relationship between study  therapy  and 
the occurrence of each AE/SAE. The Investigator will use clinical judgment to determine if there is a reasonable  possibility  that the pharmacological  action of the 
study agent was responsible for the AE/SAE being reported. Alternative causes such  as natural  history  of the underlying diseases,  concomitant  therapy,  other  risk 
Confidential  36 October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  
factors, and the temporal relationship of the event to the study agent will be 
considered and investigated. The Investigator will also consult the Investigator’s Brochure and/or Product Information, for mark eted products, in the determination 
of his/her assessment.  
 
All AE/SAE  that occur  during the course of the clinical study  will be evaluated and 
a determination of relatedness to the investigational product (CAP -1002 or 
placebo) will be defined according to one of the following categories:  
 
Related: The AE/SAE is clearly related to the investigational product.  
Not related: The AE/SAE is clearly NOT related to the investigational product. 
Unable to Determine: The investigator should make every attempt to assi gn 
causality based on his best clinical judgment, all available information about the investigational  product,  and consultation with the Capricor  chief  medical  officer. In 
the rare case  causality  cannot  be determined,  “unable to determine”  may be used; 
however,  for determining whether  an event  meets  expedited  reporting 
requirements,  “unable to determine”  shall be treated the same as a “related”  event.  
 
There may be situations when an SAE has occurred and the Investigator has minimal information to include in the initial report.  However,  it is very important  that 
the Investigator make an assessment of  causality.  
 
7.13.4 Expectedness 
 
The following events are those that could be expected to occur as a result of the catheterization and infusion procedure:  
• Premature ventricular contractions, non- sustained ventricular tachycardia  
• Possible atrial tachyarrhythmias (e.g. atrial  fibrillation).  
• Possible bradycardias and conduction block  
• Hypotension (Systolic Blood Pressure <80mmHg) with symptoms, requir ing 
intravenous fluid administration, during the cell infusion procedure 
• Desaturation below  90% requiring  O
2 administration or up titration  of O 2 
• Bleeding and /or hematoma formation at the site of vascular access for  the 
cell infusion procedure.  Complications  such  as pneumothorax or pulmonary 
artery rupture are extremely rare S AE of any cath procedure and are not 
anticipated. ( Access using ultrasound guidance and safe process  for balloon  
inflation  to determine PCWP)  
 
Note : For this study, the standard definitions of non- sustained and 
sustained ventricular tachycardia will be employed:  
- non-sustained VT: “ventricular tachycardia with a heart rate 
of at least 120 beats per minute, lasting for at least three beats  and 
persisti ng less than 30 second”  
- sustained VT: “ ventricular tachycardia that lasts more than 
30 seconds and leads to hemodynamic  collapse 
Confidential  37 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12 , 2020 
 
All adverse eve nts expected or otherwise, should be reported in the patient data. 
Serious adverse events should be reported to the Sponsor within 24 hours of the 
site learning of the event.  
 
 
7.13.5 Clinical Significance 
 
An abnormal  lab value  or test result  should be deemed clinically  significant  if either 
of the following conditions is  met: 
 
The abnormality suggests a disease and/or organ toxicity that is new or has worsened from baseline. The abnormality is of a degree that requires additional active management, e.g. , change of dose, discontinuation of a drug, close 
observation, more frequent follow -up assessments, or further diagnostic 
investigation.  
 
A qualified physician at the investigative site, either the Investigator or a Sub-  
Investigator, will review all stud y-related laboratory and other test results. The 
reviewing Investigator will use his/her medical judgment to classify and document any results that are outside of the normal results range. The Investigator indicate whether the abnormal result is clinically  significant (CS) or not clinically significant 
(NCS) on the source document and CRF. The Investigator will also date and sign the source document next to the circled abnormal result.  
 
Once the Investigator deems an abnormal value to be clinically signific ant (CS), 
he or she will determine whether there is a clinical exam finding or symptom (new or pre-existing)  that explains  the abnormal  value.  A progress  note summarizing  the 
findings, including the reason(s) why the results are deemed CS will be written t o 
provide documentation for an adverse event report. If the Investigator is able to provide a differential  diagnosis  for the CS result,  he or she should  describe the AE 
accordingly,  e.g., urinary  tract infection or suspected anemia.  In the absence of an 
associated clinical sign or symptom, and if only a single value is deemed CS, list the abnormal value itself as the AE, e.g., elevated potassium or decreased calcium. As more information about the abnormal value is known that provides a diagnosis, the AE s hould be updated in the electronic data system to reflect the 
diagnosis.  
 
 
7.13.6 Clinical Laboratory Adverse Events 
 
Abnormal laboratory findings (e.g. clinical chemistry, hematology, and urinalysis) that are judged by the Investigator  as clinically  significant  (CS) will be documented 
as described in Section 7.13.5 and will be recorded as AEs or SAEs if they meet the definition of an AE as defined in Section 7.13 or SAE, as defined in Section 7.13.7.1.  
Confidential  38 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12 , 2020 
 
Clinically significant abnormal laboratory findings that are detected during the 
study or are present at baseline and significantly worsen following the start of the study will be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings that are associated with the disease being studied, unless judged by the Investigator as more severe than expected for the patient’s condition,  or that are present  or detected at the start of the study  but do not worsen, 
will not be reported as AEs or  SAEs.  
 
The Investigator will exercise medical judgment in deciding whether abnormal laboratory values are clinically significant.  
 
 
7.13.7 Serious Adverse Events 
 
7.13.7.1  Definition 
 
A serious adverse event (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, in- patient hospitalization or prolongation of existing 
hospitalization, a persistent or significant disability/incapacity, a congenital anomaly/birth defect or important medical event.  
 
Important medical events that may not result in death, be life threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the patient and may 
require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergi c 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.  
 
Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious.  Hospitalization  for elective  treatment  of a pre-existing  condition that 
did not worsen from baseline is not considered to be an AE. 
 
The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences  of relatively  minor  medical  significance such  as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, accidental trauma (i.e., sprained ankle) that may interfere or prevent everyday life functions but do not constitute a substantial  disruption.  
 
7.13.7.2  Reporting Serious Adverse Events 
 
 
Confidential  39 October 12, 2020   
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002)  
October 12 , 2020 
 
 
 
Step 1-  If an SAE occurs that is possibly related to protocol, procedure or product, the 
study site will notify the following within 24 hours:  
1- Sponsor (Cedars -Sinai Heart  Institute)  
2- Regress -HFpEF DSMB 
3- MUSC IRB  
4- Capricor  
 
Step 2-  Send most current, updated SAE CRF and other available documentation to 
DSMB within 72 hours (3 days). Every attempt will be made to obtain al l necessary 
documentation from all involved health care providers and facilities both MUSC and any 
other location. However, even if documents and information are “pending”, the DSMB will be sent all currently available information in this timely fashion.  
 
Step 3-  DSMB will complete adjudication using the adjudication SAE form within 5  days. 
However, if the DSMB requests additional information, documentation or primary documents or if the study site receives additional information, revised adjudication by the DSMB may occur. The DSMB will send the results of the adjudication to the study site who will in turn send the adjudication result to the Sponsor.  
 
Step 4-  FDA will be informed by the Sponsor of the DSMB adjudication within 5  days after 
the adjudication is completed by the DSMB.  
 
Step 5-  If, based on the DSMB adjudication, and, at the request of the DSMB, a change in 
the Clinical Protocol needs to be made, the following sequential steps will be taken and completed within 30 business days after the adjudic ation is completed:  
1- The study site will revise the Clinical Protocol.  
2- The study site will submit these changes to the MUSC IRB for review and approval.  
3- The study site will send the revised clinical protocol to the Sponsor for review and 
approval.  
4- The Sponsor will send the revised clinical protocol to the FDA for review and approval.  
 
After DSMB review of an SAE is completed, a clear record will be established of the 
adjudication, recommendations, and sponsor follow -up. 
Site notification of SAE a nd all other communications regarding the SAE will be sent to 
sponsor, DSMB, IRB as appropriate by email together with all appropriate SAE CRFs and a paper copy of this email and any email response will be kept in the individual patient binder. The DSMB completed SAE adjudication form will be sent to sponsor by email and a paper copy of this email and any email response will be kept in the individual patient binder. All communications regarding SAE will be sent to FDA by the sponsor.  
 
Specific SAEs to our patient population are those included in the definition of clinical worsening as defined above. For example:  
 
 Death (all -cause mortality) 
 Hospitalization for worsening HFpEF: 
- Non-elective hospitalization for ≥ 24 hours  
Confidential  40 October 12, 2020   
   IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
- Signs and symptoms of LV failure to include one or more of : 
increased dyspnea, clinically significant deterioration in exercise 
capacity, syncope or pre- syncope, hypoxemia, edema, 
hepatomegaly,  ascites  
 
 
Confidential  41 October 12, 2020   
 IND Sub mission: Revision #3  
Allogeneic Cardio sphere -Derived Cells (CAP -1002)  
October 12, 2020 
 
Per ICH E2A and 21 CFR 312, regulatory agencies will be notified by the 
Sponsor  by telephone or fax of any unexpected, serious adverse event 
potentially associated with treatment as soon as possible, but in no event later than 14 business  days after the Sponsor’s initial receipt of the 
information; fatal or life -threatening unexpected SAEs associated with 
treatment will be reported to regulators within 14 business  days. Follow -up 
information will be provided as required.  
After the initial AE/SAE report, the Investigator is required to proactively 
follow each patient and provide further information to the medical monitor on the patient’s condition. All AEs and SAEs documented at a previous visit/contact  that are designated as ongoing  will be reviewed at subse quent 
visits/contacts.  
 
Adverse events and SAEs will be followed until resolution, until no further changes in the event are expected (i.e. the point at which a patient experiencing a critical adverse event is treated successfully and stabilized even thoug h they may continue to experience lingering sequelae that may 
never resolve), until the patient is lost to follow -up, or until it is agreed that 
further follow -up of the event is not warranted (e.g. non- serious, study 
therapy unrelated, mild or moderate adverse events ongoing at a patient’s final study visit). If a patient dies during participation in the study or during a recognized follow- up period,  the DSMB will be provided with a copy  of any 
post-mortem findings,  including  histopathology.  New or updated information 
will be recorded by modifying the AE forms in the paper  CRFs.  
 
The Investigator will promptly report all SAEs within the timeframes specified above. The Investigator will comply with the applicable local 
regulatory requirements related to reporting of SAEs to his or her Institutional Review Board (IRB).  
This protocol is being filed under an Investigational New Drug (IND) application with the FDA in the US. A given SAE may qualify for an Expedited Safety Report (ESRP) if the SAE is both attr ibutable to study 
therapy and unexpected. In this case, all Investigators participating in the study will receive the ESR. The purpose of the ESR is to fulfill specific regulatory and Good Clinical Practice (GCP) requirements regarding the product under investigation.  
 
7.13.7.3  Sponsor Monitoring of Adverse Events 
 
This study  will be overseen by an independent  data safety  monitoring board 
(DSMB)  appointed by the Sponsor , which  will have access to all the reports 
of patients receiving CAP -1002 infusion.  
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
   
• The following list summarizes the Sponsor’s  role in monitoring AE/SAEs:  
• All AEs will be reviewed on a monthly basis by the study  site. 
• All SAEs will be reviewed by the DSMB within 5 days of receiving the 
adverse event form from the clinical  center.  
• If the DSMB requires additional information to make an assessment, the 
clinical centers will respond to the request for additional  information  as 
soon as the requested information is made available.  
• The Sponsor  is responsible for notifying the DSMBs  of all SAEs,  and of 
any concerns regarding the frequency or type of SAE(s) on a study or 
treatment  cohort.  
• The attribution, and expected/unexpected nature of event as assessed 
by the clinical center, will be provided to the DSMBs within 5 days  of 
receiving the report.  
• All SAEs  deemed at least  possibly  related to study  treatment will also be 
sent to the DSMB within 72 hours  of the Sponsor  becoming aware of the 
event.  
 
The Sponsor  will prepare summary reports every annually  of all 
AEs/SAEs occurring in all enrolled patients for the DSMB.  
 
7.13.7.4  DSMB Monitoring of Adverse Events 
 
The following list summarizes roles of the DSMBs in monitoring AE/SAEs:  
• The DSMB will review SAEs with at least a possible relationship to study treatment within 5 days  and all other SAEs in advance of every 
DSMB meeting.  The Sponsor  anticipates  (1) phone conversation with 
DSMB chair within 5 days  of every death or life- threatening event, and 
(2) communications  within  5 days  for all other  SAEs  with at least  a 
possible relationship to the study therapy. The DSMB chair (or designee) will be requested to acknowledge receipt of SAEs within 5 
days  of notification.  
• On an annual basis  the DSMB will be provided with a summary of all 
AEs and SAEs, regardless of attribution, and additional safety and 
outcomes  data as part of their scheduled interim  reviews.  In addition to 
AE and SAE review,  specific  safety  and outcomes  data will be identified 
for review by the DSMB.  
• The DSMB Chair (or designee) is responsible for reviewing the SAE 
materials to determine if the documents are complete. If there are any concerns  regarding the type or frequency  of the event,  the DSMB Chair 
may request additional information from the Sponsor . The DSMB Chair 
will determine whether additional DSMB review is required and make recommendations to the Sponsor and study site regarding continuation of the study.  
 
 
 
42
 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  7.13.7.5  Data Safety Monitoring Board: Further  Specifics 
 
An independent Data Safety and Monitoring Board (DSMB) will oversee 
the safety of all subjects. Interim data reviews will be conducted at times coincident with regularly scheduled meetings of the DSMB in accordance with reaching accrual and follow up milestones. The DSMB Chair will be notified each time that an SAE occurs.  The DSMB  will evaluate blinded AE 
data (including SAEs) as group A vs B without identification as CDC vs Control  unless  there  is a safety  signal  present  in one of the 2 groups,  then 
the data will be reviewed in an unblinded manner. The DSMB will review data after all 10 subjects  have completed their three- month study  visit. The 
DSMB will then review the data after 20 subjects have completed their month 3 follow up visits. The DSMB will then review the data after 40 subjects have completed their month 3 follow up visits. All patients will continue to undergo protocol  assessments  through 12 months  of follow- up, 
including DSMB reviews.  
 
The DSMB will review all safety parameters. Monitoring of key safety endpoints  will be conducted as described above.  Policies  of the DSMB are 
described in the DSMB Charter.  The stopping guidelines  serve  as a trigger 
for consultation with the DSMB for additional review, and do not mandate 
automatic closure of study enrollment. Stopping will be at the discretion of the Sponsor, after consideration of DSMB recommendation. The Sponsor always retains the final responsibility t o stop a study. Given the 
complexities of the disease and treatment there cannot be more specific stopping rules.  
 
After DSMB review of an SAE is completed, a clear record will be established of the adjudication, recommendations, and sponsor follow -up. 
Site notification of SAE and all other communications regarding the SAE 
will be sent to sponsor, DSMB, IRB as appropriate by email together with all appropriate SAE CRFs and a paper copy of this email and any email response will be kept in the individual pati ent binder. The DSMB completed 
SAE adjudication form will be sent to sponsor by email and a paper copy of this email and any email response will be kept in the individual patient binder. All communications regarding SAE will be sent to FDA by the sponsor.  
 
 
7.13.8 Post -Study Adverse Events and Serious Adverse Events 
 
The Sponsor will notify  the DSMB of any death or SAE occurring at any time after a 
patient  has completed  or terminated a clinical trial, when  such  death or SAE may 
reasonably be related to the study therapy used in this investigational trial. Investigators  are not obligated to actively  seek  AEs from former study  participants.  
  
43 
 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
  7.13.9 Treatment -Emergent Adverse Events  
 
Adverse event assessment and documentation will occur at every study visit from 
screening throughout  the study.  On the day of treatment  administration,  a patient’s 
medical complaint will be considered to be a treatment -emergent adverse event if 
the event occurs any time after the infusion of CAP -1002 or  placebo.  
 
7.14 Concomitant Medi cation Assessments 
 
Study personnel will record both general and cardiac medication use at each study visit beginning at the time of enrollment. Concomitant medications are defined as those received on or after the day of infusion.  All medications  will be reviewed by the 
Investigator at individual study sites and will then be entered into the CRF for each study visit.  
  
7.15 Removal of Patients from the Trial or Study Drug  
 
The Investigator may withdraw a patient from participation in the study for 
any of the following reasons : 
• A protocol violation occurs  
• A serious or intolerable adverse event  occurs  
• A clinically significant change in a laboratory parameter  occurs  
• The Sponsor or Investigator terminates the study,  or 
• The patient requests to be discontinued from the study.  
7.16 Other Study Procedures 
 
For patients who so consent, serum for clinical research into biomarkers will be 
collected at every scheduled visit.  
 
7.17 Appropriateness of  Measurements 
 
Usual  safety  measurements  will be obtained and summarized per standard 
reporting. In addition,  more  in depth evaluation of safety  data as it relates  to 
cardiac  events  will more  fully elucidate the safety  profile  for CAP- 1002.  Events  to 
be assessed  in greater detail hav e been mentioned under primary and secondary  
end-points.  
 
This is a phase IIa study with a primary objective to evaluate the safety of the coronary  artery  infusion of CAP- 1002 in patients  with HFpEF.  In addition to the 
safety end- points, information on numerous potential measures of efficacy, as 
mentioned previously, will also be collected, which will be considered only exploratory to help guide possible future clinical  trials.  
 
44 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
   
8. STUDY  ACTIVITIES  
Patients qualifying as potential candidates for the study, based on initial preliminary 
screening,  will be consented for the procedure.  Patients  meeting the screening criteria  for 
the study will be consented for CAP -1002 infusion.  
 
The final eligibility of the patient for the study will depend on the hemodynamic profile of the patient  with patient  meeting all inclusion  and exclusion criteria. Patients  who meet  all 
of the inclusion criteria and none of the exclusion criteria will receive intracoronary infusion of CAP- 1002. Study patients will be observed in the hospital with continuous cardiac  and 
respiratory  monitoring for at least  24 hours  afterwards.  
 
8.1 Pre-Treatment Screening Phase (Days - 28 to -1) 
No screening exams will take place until the patient is fully informed of the research and signs the informed consent.  
 
 
Screening tests and procedures include:  
• History and physical  examination  
• Vital Signs  
• Medication  review  
• NYHA functional class  assessment  
• 12 lead ECG  
• Biomarkers  
• 24-hour ECG  
• Echocardiography  
• 6MWT 
• Laboratory  tests  (hematology,  chemistry,  BNP,  pregnancy  test [if applicable]  and 
HLA/DSA, troponin -I, CPKMB)  
• Chest  CT 
• Cath and bicycle ergometry  
• Baseline contrast enhanced cardiac MRI; (unless  contraindicated);  
• Baseline Patient Quality of Life Questionnaire (MLWHF)  
Following  screening examinations,  once a patient  has met all of the inclusion  criteria 
and none of the exclusion criteria, the patient will undergo further hemodynamic screening. For those enrolled in the study, dosing and randomization will be 
coordinated with Capricor  and the Research Pharmacy  at MUSC.  The test agent  will 
be prepared according to instructions in the Pharmacy Manual. The test agent will then be drawn into the syringes using sterile technique for administration during the cath procedure.  
45 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020   
   
 
 
8.2 Hemodynamic Screening 
 
The final eligibility of the patient will be determined based on the presence of hemodynamic inclusion criteria and absence of hemodynamic exclusion criteria. Patients who do not proceed to infusion due to violation of eligibility criterion at  screening will be withdrawn from 
the study as screen failures and will have no further follow up.  
 
8.2.1  Intracoronary Infusion Procedure (Day 0) 
 
During the infusion period, patients will be clinically stable as judged by no evidence of infection, and stable blood pressure, pulse and pulse Ox.  
 A pati ent is enrolled and randomized in the study once the patient receives any amount of 
test agent. Conversely, a patient who does not receive any test agent is not considered enrolled or randomized in the study. If the operator decides not to administer the t est agent, 
the patient is not enrolled or randomized, and subsequent treatment will be determined by the responsible physician and will not be protocol - driven. In addition, only those subjects 
that are enrolled, randomized, and receive any amount of test agent will be considered in the statistical analysis plan.  
 Prior to cell infusion, all patients will have a pulmonary artery catheter inserted and coronary  catheters  using  standard technique in the cardiac  catheterization laboratory. 
Baseline (pre- infusion) hemodynamics will be made. Provided no hemodynamic contra-
indications to proceed, cell infusion will be done. During the infusions, vital signs, SP
O2 and 
pulmonary artery hemodynamics will be monitored 
 Stopping criteria that would trigger halting of the CAP -1002 infusion are:  
 
• Hypotension unresponsive to IV fluids that require pharmacologic intervention  
• VT/ventricular fibrillation that require cardioversion or administration of an 
antiarrhythmic.  
• Changes in cardiac rhythm or conduction (such as SVT, atrial fibrillation with rapid ventricular response or heart block) that requires cardioversion or administration of an antiarrhythmic.  
• Significant hypoxemia/desaturation not corrected by supplemental oxygen or IV  
diuretic (if volume overloaded) or reversal of sedation (if over sedated)
 
• Suspected or confirmed pulmonary artery  rupture.  
• Suspected or confirmed coronary  dissection.  
• Acute onset of rigors or elevated temperature above 99.8oF (symptoms indicative 
of acute sensitivity or  infection)  
   
46
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
  
Following infusion, patients will be observed in the hospital for at least 24 hours with 
continuous cardiac and respiratory monitoring. Note, hemodynamic measurements  will 
be obtained if clinically  indicated  (e.g. fall in blood pressure),  prior to  withdrawal  of PA 
catheter  in the cardiac  catheterization laboratory  over the 1-hour time frame  post CDC  
infusion,  at which  time the patient  will be assessed as stable to transfer to the hospital . 
Additionally,  troponin I and CK-MB will be obtained.  
 
Cardiac Arrhythmia Monitoring: The electrocardiogram will be continuously monitored  
during the intracoronary  infusion and while  patients  are in the hospital  after the  procedure.  
IND Submission: Revision #1  
 
Prior to discharge from the hospital, a physical assessment will be performed. The latter 
includes evaluation of symptoms of dyspnea, chest pain, and dizziness with effort. The 
following will also be assessed: O 2 needs, serial BP and HR, administration of an 
antiarrhythmic or cardioversion, administration of an inotrope, review  of laboratory  results,  
ECG,  and assessment  of adverse events.  In the absence of  serious  adverse events,  
patients  will be discharged per standard of care practice.  
 
The timing of follow -up visits is based on the date of study therapy administration.  
8.2.1.1 Post infusion of CAP -1002  
• History and physical  examination  
• Medication review  
• Adverse events  assessment  
• 12 lead ECG  
• Laboratory examinations (including troponin I and CK-MB) 
• Troponin and CK -MB will be drawn 8, 16 and 24 hours post infusion  
• If Troponin is not down trending at 24 hours post infusion, the patient will remain in 
hospital until they reach down trending pattern.  
 
Pre Discharge an ins truction sheet will be given to patient and reviewed with study 
coordinator  
 24-48 hours after discharge, the patient will be contacted by the study coordinator to check 
on patient condition and r/o AE or SAE occurance.  
8.2.2  2 Week Visit (Day 14 +/- 4 days)  Procedures 
The following will be performed at the 2- week visit:  
• History and physical  examination  
• Medication review  
• Adverse events  assessment  
• 12 lead ECG  
• Laboratory examinations (hematology, chemistry, DSA,  BNP)  
• Biomarkers  
• NYHA functional class  assessment  
• 24 hour  ECG  
         
       47 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
  
 
Outpatient visits will be completed as close to the scheduled visit dates as possible. The 
visit window is ± 4 clinic days from the intended date of the visit.  
 
8.2.3  3 Month Visit (Day 90 +/- 14 days)  Procedures 
The following will be performed at the 3- month visit:  
• History and physical  examination  
• Medication review  
• Adverse events  assessment  
• 12 lead ECG  
• Laboratory examinations (hematology, chemistry, DSA,  BNP)  
• Biomarkers  
• NYHA functional class  assessment  
 
8.2.4  6 Month Visit (Day 180 +/- 14 days)  Procedures 
The following will be performed at the 6- month visit:  
• History and physical  examination  
• Medication review  
• Adverse events  assessment  
• 12 lead ECG  
• 24 hour  ECG  
• Echo  
• MRI 
• Laboratory examinations (hematology, chemistry, DSA,  BNP)  
• Biomarkers  
• NYHA functional class  assessment  
• 6MWT 
• Quality of Life assessment  
• Cath /  ergometry  
 
8.2.5  12 Month Visit (Day 360 +/- 30 days)  Procedures 
The following will be performed at the 12- month visit: 
• History and physical  examination  
• Medication review  
• Adverse events  assessment  
• 12 lead ECG  
• Echo  
• Laboratory examinations (hematology, chemistry, DSA, BNP  ) 
• Biomarkers  
• NYHA functional class  assessment  
• 6MWT 
• Quality of Life assessment  
48 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
 Note: Outpatient visits will be completed as close to the scheduled visit dates as 
possible. The visit window is ± 30 clinic days from the intended date of the visit.  
 
8.3 Payments to Patients  
Patients  will be reimbursed $50 for each of the 2-week,  3-month and 6 and 12-month visits. 
These di sbursements are intended to cover the costs required to complete these study  
visits.  Necessary  travel  expenses  (reasonable hotel,  meals  and fuel) and parking 
expenses may be reimbursed.  
8.4 Early Termination Procedures  
Every reasonable effort will be made to retain patients in the study. In the event that a 
patient must be withdrawn from the study early, study personnel should attempt to obtain 
testing and data required for the 1- month primary safety end- point visit (See  Section 
8.3.3) as well as the reason for withdrawal, if known. If the patient permits, he or she should be contacted by study personnel at the time of their usual study visits to obtain adverse event information.  
 
Follow- up of adverse events  that result  in discontinuing the patient  from the study  will 
continue until resolution, until the event has stabilized, or until the event has been determined to be caused by an agent other than the study  drug.  
 
Patients who withdraw from the study due to pregnancy wil l be followed during the 
pregnancy and through birth of the newborn.  
 
A patient can be considered “lost to follow -up” if he or she misses a visit and study 
personnel  are unable to contact him or her in a timely manner with a minimum of 
three documented phone calls.  
 
If contact with the patient is not accomplished, study personnel will follow -up with 
certified mail in the following manner:  
1. Mail a certified letter with return receipt requesting contact and expressing concern for the patient’s  well-being.  
2. If the patient  does  not respond within  seven days,  mail another  certified  letter  with 
return receipt stating that the patient’s participation in the study has been termi nated.  
3. If a signed mailing  receipt  for the second letter  is returned,  record the termination 
date as the date the patient signed it. Otherwise, record the termination date as the date the second letter was  mailed.  
 
Stopping Rules Statement:  
 
Stopping Rules that will result in temporary suspension of enrollment and dosing until the situation can be fully assessed and addressed will be defined by the independent DSMB. The DSMB may also request additional interim analyses and develop other criteria for determining when to intervene in the enrollment or treatment of patients in the study. Monitoring of primary safety endpoints will be conducted. All SAEs will be reported to the DSMB for review.  
        49 
IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
  
The DSMB will carefully evaluate the safet y of all patients, including the following:  
 
 Death (all -cause mortality) 
 
 Hospitalization for worsening HFpEF: 
 
- Non-elective hospitalization for ≥ 24 hours  
 
- Signs and symptoms of LV failure to include one or more of: increased 
dyspnea, clinically significant deterioration in exercise capacity, syncope or pre-syncope,  
 
- hypoxemia, edema, hepatomegaly,  ascites  
 
9. QUALITY CONTROL AND ASSURANCE  
Data  will be entered into the REDCap  clinical database.  A detailed description of the data 
collection tools  and data management  process  can be found in the CRF completion  
guidelines  and other  data management  materials.  The study  site must  ensure appropriate 
source data documentation. The Investigator or designee must enter all required patient data in a timely  fashion and an explanation must  be documented for any missing  data.  
             
 
      
              50 
 
Confidential   October 12, 2020  
 IND Submission: Revis ion #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
  
10. PLANNED STATISTICAL  METHODS  
Statistical analysis : An independent DSMB, with roles and responsibilities defi ned in a 
written charter, was  be appointed to oversee safety of the study. The DSMB will consist 
of a three heart failure cardiologists, one with additional expertise in an interventional 
cardiology, one with additional expertise in imaging, one with additional exper tise in 
transplant/immunology , and a statistician. The DSMB may also request additional interim 
analyses and develop other criteria for  determining when to intervene in the enrollment 
or treatment of subjects in the study. Monitoring of all safety endpoints will be conducted. 
Individual cases reported to regulatory bodies will also be reported to the DSMB Chair  
and will be reviewed  by the DSMB at each  meeting.  The DSMB will also have access to 
reports evaluating group trends relative to CAP -1002 vs. Control as well as relative to the 
literature for CAP -1002- treated subjects. In addition, any external concerns regarding 
CAP- 1002 safety will  be brought to the attention of the DSMB.  
The proportion of subjects experiencing an adverse event  or a protocol -specific safety 
event (PSE) will be monitored at pre- planned intervals set by the DSMB. A futility chart 
will be created to allow  for DSMB safety  monitoring.  The excess for CAP- treated subjects 
is of primary concern as Phase 2a data accrue. The boundaries will be computed using StatXact v7 (CyTel, Cambridge MA); a one- sided 95% exact test was performed 
assuming binomially distributed outcomes. The chart will be applied to any binary outcome pertaining to safety. The chart will be computed over a broad range of possible PSE outcomes. No adjustment for Type I error will be made for repeated looks since the ultimate decision regarding safety represents a clinical decision involving all safety endpoints  in the context  of efficacy.  Descriptive  summaries  will be provided for all primary 
and secondary endpoints for both safety and efficacy. A prospective statistical analysis plan (SAP)  will be generated with DSMB review  and input.  . All analyses  will be performed 
using SAS Version 9.2 or  greater.  
Efficacy data will be presented as mean changes from screening at designated visits. This Phase 2a data will be used to calculate effect sizes for planning subsequent Phase 2b studies.  If there  are sufficient  follow- up data,  longitudinal  models  (SAS PROC MIXED 
for continuous endpoints and SAS PROC GENMOD for binary endpoints) will be explored.
52-56 A formal  SAP will be developed  in a collaboration as described earlier.  
 
10.1 General  Considerations  
Descriptive summaries will be provided for all primary and secondary end- points. All 
analyses  will be performed using SAS Version  9.2 or greater.  An independent  DSMB 
will monitor  the study  and make recommendations,  if needed,  regarding stopping the 
study due to safety  concerns.  
10.2 Analysis Populations 
Patients receiving CAP -1002/placebo infusion will be followed for 12 months. 
Patients will have study visits at 24- 48 hours post discharge 2 weeks, 3, 6 & 12 
months following infusion.  
The analysis  population for assessing safety  objectives  will consist  of all patients  who 
received an infusion of CAP -1002. For patients with missing follow -up data points, 
missing data will be imputed using predefined rules detailed in the SAP.  
       
      51 
Confidential   October 12, 2020  
 IND Submission: Revis ion #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020 
 
  
  
10.3 Demographics and Baseline Characteristics 
Demographics and baseline characteristics of all accrued patients such as race, ethnicity,  gender  and age will be summarized and reported.  The gender  and minority 
distributions  are expected to reflect the HFpEF population in the United  States.  There 
are no particular recruitment strategies for gender or minorities. We expect a high percentage of women in the HFp EF population.  
10.4 Interim  Analysis 
The DSMB will be reviewing  the data over the course of the study  to assess the safety 
of CAP- 1002 infusi on.  All interim analysis are described above.  
 
11. ADMINISTRATIVE  CONSIDERATIONS  
11.1 Investigators and Study Administrative  Structure 
 
Information regarding the study will be posted at http:/www.c linicaltrials.gov  in the 
listing  for this study.  Should a question arise  during the study  from the Investigator  or 
study staff or should a SAE occur, the staff should contact the Regress- HFpEF 
DSMB using the contact information below:  
Theo Meyer meyert@ummhc.org
 
(508) 856- 2224  
 
The lead Principal Investigator is Michael R. Zile, MD, 
MUSC. MUSC will be responsible for enrolling subjects.  
A core imaging group (Dr. Litwin, MUSC) will be used to centrally read all echocardiography, CT, MRI studies and a core laboratory (UCLA Immunogenetics Center) will be used to analyze samples for HLA/donor specific antigens. A core hemodynamics lab (Dr. Fernandes, MUSC) will read all cath data.  
 
In order to ensure quality and continuance of patient care, the PI will inform patients primary cardiac care physician of his/her participation in HFpEF Study.  
11.2 Institutional Review Board (IRB) Approval  
 
It is the Investigators’ responsibility to ensure that, prior to initiating this study; this protocol  is reviewed and approved  by the appropriate local Institutional  Review Board 
(IRB). The composition and conduct of this committee shall conform to the United States CFR and ICH  E6. 
          52
Confidential   October 12, 2020  
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
 October 12, 2020 
The IRB will also review and approve the site’s informed consent form (ICF), other 
written information provided to the patient and all advertisements that may be used 
for patient recruitment.  
 
If it is necessary to amend the protocol or the ICF during the study, the Investigator will be responsible for ensuring that the IRB reviews and approves these amended documents. An IRB approval of the amended protocol and/or ICF must be obtained in writing  before implementation of the amended procedures  and before new patients 
are consented to participate in the study using the amended version of the ICF. 
 
11.3 Ethical Conduct of the Study  
 
This study will be conducted in accordance with Good Clinical Practice (GCP) requirements described in the current revision of International Conference on Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH) Guidelines and all applicable regulations, including current United States Code of Federal Regulations (CFR), Title 21, Parts 11, 50, 54, 56, and 312 and Title 45, Part  
164. Compliance with these regulations and guidelines also constitutes compliance with the ethical principles described in the current revision of the Declaration of Helsinki. This study will also be carried out in accordance with local legal requirements.  
 
11.4 Patient Information and Consent  
 
Before being admitted to the clini cal study, all patients must consent in writing to 
participate. An ICF will be given to each patient, which will contain all United States federally required elements, all ICH -required elements, and Health Insurance 
Portability and Accountability Act (HIPAA) authorization information in language that is understandable to the patient.  
 
The process of obtaining the informed consent will be in compliance with all federal regulations, ICH requirements, and local laws.  
 
The Investigator will review the study with each patient. The review will include the 
nature, scope, procedures, and possible consequences of the patient's participation in the study. The ICF and review will be in a form understandable to the patient. The Investigator  or designee and the patient  must  both sign and date the ICF after review 
and before the patient can participate in the study. The patient will receive a copy of the signed and dated form,  and the original  will be retained in the site study  files. The 
 
Investigator or his/her designee will emphasize to the patient that study participation 
is entirely  voluntary  and that consent  regarding study  participation may be withdrawn 
at any time without penalty or loss of benefits to which the patient is otherwise entitled.  
      53 
      
 
Confidential   October 12, 2020  
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
 If the ICF is amended during the study, the Investigator must follow all applicable 
regulatory requirements pertaining to approval of the amended ICF by the IRB/IEC. The site must use the amended consent form for all new patients and repeat the consent process with the amended ICF for any ongoing patients.  
 
11.5 Patient  Confidentiality 
 
Patients’  names  will remain confidential  and will not be included in the database.  Only 
patient number, patient initials, and birth date will be recorded in the data system. I f 
the patient name appears on any other document collected (e.g., hospital discharge summary), the name will be obliterated before the document  is transmitted. All study 
findings will be stored in paper CRFs. The patients will give explicit permission for representatives of the Sponsor, regulatory authorities, and the IRB/IEC to inspect their medical records to verify the information collected.  
 
Patients will be informed that all personal information made available for inspection will be handled in the strictest  confidence and in accordance with all state,  local,  and 
federal  data protection/privacy  laws,  including,  without  limitation,  the HIPAA.  
 
All participants  in the study  will provide written  authorization to disclose  private health 
information either as a part of the written ICF or as a separate authorization form. 
The authorization will contain all required elements  specified by 45 CFR 164 and ICH 
E6 as applicable, and will contain a waiver of patient access to study -related private 
health information until the conclusion of the clinical study. The authorization will 
remain valid and in full force and effect until the first to occur of (1) the expiration of 2 years  after the study  therapy  is approved for the indication being  studied,  or (2) the 
expiration of 2 years after the research program is discontinued. Individual patient medical information obtained during this study is confidential and its disclosure to third par ties (other than those mentioned in this section) is strictly prohibited. In 
addition, medical information obtained during this study may be provided to the patient's  personal  physician or to other  appropriate medical  personnel  when required 
in connection with the patient's continued health and welfare.  
 
The study site will maintain a personal patient identification list (patient and treatment numbers with the corresponding patient names) to enable records to be identified.  
 
11.6 Study Monitoring  
The DSMB  Chair  will also serve  as study  monitor  and will determine the frequency  of 
monitoring visits  primarily  based on enrollment  and compliance with protocol -dictated 
procedures, with visits generally occurring once every 12 months. The DSMB Chair 
will have cont inuous access to the electronic data capture system to review 
completion of study documents, and data and adverse event reporting in a timely manner.  
 
      54
Confidential   October 12, 2020  
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
  
11.7 CRFs and Study Records 
 
All CRFs will be completed in accordance with GCP guidelines and as soon as 
possible after each clinical trial visit.  
 
REDCap will be utilized to record all of  the protocol -required information to be 
reported to the Sponsor on each trial subject. Study personnel will be trained in how 
to access and use the REDCap to enter and transmit data for the study. Study personnel will be trained regarding proper correction of data entries in the REDCap.  
 
Study personnel are responsible to ensure that all entries are accurate, legible and verifiable with the source data in the medical record. A source document is defined as the place in the medical record where a given data point first appears. REDCap 
will not serve as source documents.  
 
11.8 Protocol  Violations/Deviations 
 
As they occur, deviations and violations will be documented and reported to the DSMB, Sponsor and MUSC IRB. Upon detection of a violation, the Sponsor will ensure reporting to the proper local and federal regulatory authorities in accordance 
with all applicable federal and local regulations. The Sponsor will determine the 
course of action  based  on the severity  of the deviation or violation.  These may include 
but are not limited to, withdrawal of the subject, additional training at the site, additional site monitoring, etc. In addition, the Site investigator and the Sponsor  and 
statistician will review the circumstances of each violation (in a blinded fashion) to determine whether the data can reasonably be included in the patient data in the final study analysis.  
 
11.9 Access to Source Documentation 
 
The Investigator,  Sponsor  and site clinical study  personnel  will be able to access  the 
source documentation.  De-identified source documentation may be accessed  by the 
Sponsor  and the DSMB,  e.g., in evaluation of an SAE.  In addition,  the study  site must 
allow trial- related monitoring audits, IRB review, and regulatory inspection(s), with 
direct access to source data and documents.  
 
11.10  Data Generation and Analysis 
 
REDCap will be utilized to collect data and generate a database. Study site will be responsible for entering data collected at the site and external data sources (i.e., central  lab and core imaging center)  are expected to provide data sets to be entered 
into the database.  
 
 
   55 
 
Confidential   October 12, 2020  
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
  
11.11  Retention of  Data  
In accordance with 21 CFR 312.62, an Investigator participating in this study shall 
retain records, including the CRFs and supporting data including signed and dated consent  forms, and medical  records,  progress  notes  of the physician,  the individual's 
hospital chart(s), and the nurses' notes. Records are required to be maintained for a period of 2 years following the date the marketing application is approved or, if no application is to be filed or if the application is not approved by the FDA,  until 2 years 
after the investigation is discontinued and FDA is notified. In any case, the Sponsor should be notified prior to the destruction of any study  records.  
 
11.12  Financial Disclosure  
 
In accordance with FDA regulatory  requirements,  21 CFR 54.4,  study  personnel  who 
are required to complete a financial  disclosure form will do so prior to participation in 
the study. Designated individuals shall provide sufficient and accurate financial information to allow the Sponsor to submit complete and accurate certification or disclosure statements  (Forms  3454 and/or  3455)  as required by the FDA regulations. 
Those individuals  shall promptly  update this information if any relevant  changes  occur 
in the course of the investigation or for 1 year following  completion of the study.  
 
                 
         
 
 56 
Confidential   October 12, 2020  
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
   
 
 
LIST OF APPENDICES  
Appendix 1: SCHEDULE OF STUDY ACTIVITIES/ASSESSMENTS 
 
 
Appendix 2: STUDY RECRUITMENT  TIMELINE  
 
 
Appendix 3: PROHIBITED CONCOMITANT  MEDICATIONS 
 
 
Appendix 4: INFORMED CONSENT  TEMPLATE  
 
 
                     
 
  
 
 
   
 
    57 
 
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
 Appendix 1: SCHEDULE OF STUDY ACTIVITIES/ASSESSMENTS  
 Post  Infusion  Months  
Study Procedure  Screening  Pre D/C  Post D/C  
Phone 
24-48 Hr  0.5 3 6 - Pre 
D/C 
 6 - Post 
D/C phone  
24-48 hr  12 
Informed Consent  x        
Medical History  x x X x x X X x 
Physical Exam  x x  x x X  x 
Medication Review  x x  x x X  x 
AE Assessment   x X x x X X x 
ECG  x x  x x X  x 
Labs  x x  x x X  x 
Biomarkers  x   x x X  x 
HLA x        
DSA x   x x X  x 
Chest CT  x        
Cath/Ergometry  x     X   
Cardiac MRI  x     X   
24-hour ECG  x   x  X   
Troponin I & CK -MB x x* 
See 
8211        
Echocardiography  x     X  x 
Six Minute Walk  x     X  x 
QOL  x     X  x 
NYHA Assessment  x   x x X  x 
D/C Instructions  
  X    X   
 
         58 
 IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
 Appendix 2: STUDY  RECRUITMENT TIMELINE  
 
 
 
          59 
 
Patient  recruitment 
2 patients/month  
Total 40 patients  
6 months 
Endpoint  
12 months 
Endpoint  
Final 
Report  
20 
 26 
 32 
0 
 12 
 24 
 36 
Time in Months  
Confidential  October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells (CAP -1002) 
October 12, 2020  
 
  
  
Appendix 3: PROHIBITED CONCOMITANT MEDICATIONS 
 
The following medications are prohibited for three months prior to enrollment in the 
study:  
 
GENERIC NAME TRADE NAME  
 
Abacavir  Epzicom®  
Abacavir  Ziagen®  
Abacavir sulfate, Lamivudine,  and Zidovudine Trizivir® 
Adalimumab Humira®  
Aldesleukin  Proleukin®  
Altretamine  Hexalen®  
Aminoglutethimide  Cytadren®  
Anakinra  Kineret®  
Anastrozole Arimidex®  
Asparaginase Elspar®  
Atazanavir  sulfate Reyatax®  
Basiliximab  Simulect®  
Bleomycin  Blenoxane®  
Busulfan  Myleran®  
Capecitabine Xeloda®  
Carboplatin  Paraplatin®  
Carmustine  BiCNU® (BCNU)  
Certolizumab pegol  Cimzia®  
Chlorambucil  Leukeran®  
Cidofovir  Vistide®  
Cisplatin  Platinol®  
Cladribine  Leustatin®  
Cyclosporine Gengraf®  
Cyclosporine Neoral®  
Cyclosporine Sandimmune®  
Cytarabine  
Cytarabine  DepoCyt® 
Dacarbazine DTIC- Dome®  
Daclizumab  Zenopax®  
Dactinomycin  Cosmegan®  
Darunavir  Prezista®  
Dasatinib  Sprycel®  
Daunorubicin  Cerubidine®  
Delavirdine  Rescriptor®  
Denileukin diftitox  Ontak®  
Didanosine  Videx®  
Docetaxel  Taxotere®  
Docetaxel  Docefrez®  
60 
 
Confidential  October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
Doxorubicin Adriamycin® 
Doxorubicin Doxil®  
Efavirenz  Sustiva®  
Efavirenz/emtricitabine/tenofovir  disoproxil  Atripla®  
Emtricitabine  Emtriva®  
Emtricitabine/tenofovir  disoproxil  fumarate  Truvada®  
Enfuvirtide  Fuzeion®  
Epirubicin  Ellence®  
Erlotinib  Tarceva®  
Estramustine  Emcyt®  
Etanercept  Enbrel®  
Etoposide  Etopophos®  
Etoposide  VePesid®  
Etravirine  Intelence®  
Everolimus  Afinitor®  
Everolimus  Zortress®  
Exemestane Aromasin®  
Floxuridine  Fluorodeoxyuridine®  
Floxuridine  Ancobon®  
Fludarabine Oforta®  
Fludarabine Fludara®  
Fosamprenavir  calcium  Lexiva®  
Gemcitabine Gemzar  
Golimumab  injection  Simponi  
Hydroxyurea Droxia®  
Hydroxyurea Hydrea®  
Idarubicin  Idamycin®  
Ifosphamide Ifex®  
Imatinib  mesylate  Gleevac  
Indinavir  Crixivan®  
Infliximab  Remicade®  
Interferon  alfa-2a Roferon- A® 
Interferon  alfa-2b Intron -A® 
Interferon  alfacon- 1) Inferge ® 
Interferon  beta-1a Avonex®  
Interferon  beta-1b Betaseron®  
Interferon  beta-1b Extavia®  
Interferon  beta-lb Betaseron®  
Interferon  gamma -1b Actimmune®  
Interleukin- 2 Proleukin  
Irinotecan Camptosar  
Lamivudine  Epivir®  
Lamivudine  & Zidovudine Combivir®  
Lanreotide  Somatuline® Depot  
Lapatinib  Tykerb®  
 
 
61 
Confidential  October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
 
 
Leflunomide Arava®  
Lenalidomide Revlimid  
Letrozole  Femara®  
Leuprolide  Lupron®  
Leuprolide  Eligard®  
Lomustine  CeeNu®  (CCNU)  
Maraviroc  Selzentry®  
Mechlorethamine HCI Mustargen®  
Megestrol  Megace®  
Melphalan  Alkeran®  
Mercaptopurine  Purinethol®  
Methotrexate  Rheumatrex®  
Methotrexate  Trexall ™ 
Mitomycin  Mutamycin®  
Mitotane Lysodren®  
Mitoxantrone Novantrone®  
Muromonab- CD3 Orthoclone- OKT3  
Nelfinavir  Viracept®  
Nevirapine  Viramune®  
Nilotinib  Tasigna®  
Octreotide  acetate Sandostatin®  
Paclitaxel  Taxol®  
Paclitaxel  Abraxane®  
Pazopanib  Votrient®  
Pegaspargase Oncaspar®  
Peginterferon alfa-2a Pegasys®  
Peginterferon alfa-2b Peg-Intron®  
Penicillamine  Cuprimine® 
Procarbazine Matulane®  
Raltegravir  Isentress®  
Ribavirin  Copegus®  
Rilonacep  Arcalyst ™ 
Ritonavir  Norvir®  
Ritonavir/Lopinovir  Kaletra®  
Rituximab  Rituxan®  
Saquinavir  Invirase®  
Sargramostim  Leukine®  
Sirolimus  Rapamune®  
Sorafenib  Nexavar®  
Stavudine  Zerit®  
Streptozocin Zanosar®  
Sulfasalazine Azulfidine  EN-tabs®  
Sunitinib  malate  Sutent®  
Tacrolimus  Prograf®  
Tamoxifen citrate                               
                                                  6 2 Nolvadex  
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
Temozolomide Temodar®  
Temsirolimus  injection  Torisel®  
Teniposide  Vumon®  
Tenofovir  disoproxil  fumarate  Viread®  
Thalidomide Thalomid®  
Thioguanine Tabloid®  
Thiotepa  
Tipranavir  Aptivus®  
Tocilizumab Actemra®  
Topotecan  Hycamtin®  
Toremifene citrate  Fareston®  
Trastuzumab Herceptin®  
Tretinoin  Vesanoid®  
Tretinoin  Vesanoid®  
Triamcinolone  Kenalog®  
Triamcinolone  Aristospan®  
Valrubicin  Valstar®  
Vinblastine 
Vincristine  
Vinorelbine  Navelbine®  
Vorinostat  Zolinza®  
Zalcitabine  Hivid®  
Zidovudine  Retrovir®  
 
 
                 
 63 
 
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
Appendix 4: Approved INFORMED CONSENT 4 -24-17 Version 
Please see attached 
 
 
           
 
           
        
    
64 
 
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
REFERENCES  
 
 
1 Zile, M. & Little, W. Heart Failure with a Preserved Ejection Fraction. , (2013).  
2 Yancy, C. et al. American College of Cardiology Foundation/American Heart 
Association Task  Force 
on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart 
failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. . Circulation 128, 240- 327 (2013).  
3 Butler, J. et al. Developing therapies for heart failure with 
reserved ejection fraction: current state and future directions. JACC Heart Fail 2 , 97-112, doi:10.1016/j.jchf.2013.10.006 
(2014).  
4 McMurray, J. J. et al. ESC guidelines for the diagnosis and treatment of acute 
and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment 
of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. 
Eur J Heart  Fail 14, 803-869, doi:10.1093/eurjhf/hfs105 (2012).  
5 Zile, M. R. et al. Mode of death in patients with heart failure and a preserved 
ejection fraction: results from the Irbesartan in Heart Failure With Preserved 
Ejection  Fraction  Study  (I -Preserve)   trial. 
Circulation 121, 1393- 1405, doi:10.1161/CIRCULATIONAHA.109.909614 (2010).  
6 Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a 
population- based study.  N Engl J Med 355, 260-269, doi:10.1056/NEJMoa051530 
(2006).  
7 Owan,  T. E. et al. Trends  in prevalence and outcome of heart  failure  with preserved 
ejection fraction. N Engl J Med 355, 251-259, doi:10.1056/NEJMoa052256 (2006).  
8 Farr, M. J. et al. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol 102, 203- 206, doi:10.1016/j.amjcard.2008.03.041 (2008).  
9 Rector,  T. S. et al. Assessment  of long- term effects  of irbesartan on heart  failure with 
preserved ejection fraction as measured by the minnesota living with heart failure 
questionnaire in the irbesartan in heart failure with preserved systolic function (I -
PRESERVE)  trial. Circ          Heart          Fail 5, 217-225, 
doi:10.1161/CIRCHEARTFAILURE.111.964221 (2012).  
10 Zile, M. R. et al. Effects of exercise on left ventricular systolic and diastolic properties 
in patients with heart failure and a preserved ejection fraction versus heart failure 
and a reduced ejection fracti on. Circ Heart Fail 6 , 508- 516, 
doi:10.1161/CIRCHEARTFAILURE.112.000216 (2013).  
11 Kristensen, S. L. et al. Comparison of  outcomes  after  hospitalization  for 
worsening heart failure, myocardial infarction, and stroke in patients with heart 
failure  and  reduced  and  preserved  ejection fraction. Eur J Heart Fail 17, 169-  
176, doi:10.1002/ejhf.211 (2015).  
 
 
 
 
 
65 
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
 
  
12 Carson, P. E. et al. The Hospitalization Burden and Post -Hospitalization Mortality 
Risk  in  Heart  Failure  With  Preserved  Ejection  Fraction:  Results  From  the   I- 
PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).  
JACC Heart Fail 3 , 429- 441, doi:10.1016/j.jchf.2014.12.017 (2015).  
13 Badar, A. A. et al. Clinical Characteristics and Outcomes of Patients With Coronary 
Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Hear t Fail 8 , 717- 724, 
doi:10.1161/CIRCHEARTFAILURE.114.002024 (2015).  
14 Yusuf, S. et al. Effects of candesartan in patients with chronic heart failure and 
preserved left -ventricular ejection fraction: the CHARM -Preserved Trial. Lancet 362, 
777-781, doi:10.1016/ S0140-  6736(03)14285- 7  (2003).  
15 Ahmed, A. et al. Effects of digoxin on morbidity and mortality in diastolic heart 
failure: the ancillary Digitalis investigation group trial. Circulation 114, 397- 403, 
doi:10.1161/CIRCULATIONAHA.106.628347 (2006).  
16 Cleland, J. G. et al. The perindopril in elderly people wit h chronic heart failure (PEP -
CHF)  study.  Eur Heart  J 27, 2338- 2345,  doi:10.1093/eurheartj/ehl250 (2006).  
17 Massie, B. M. et al. Irbesartan in patients with heart failure and preserved ejection 
fraction. N Engl J Med 359, 2456- 2467, doi:10.1056/NEJMoa0805450 (2008).  
18 van Veldhuisen, D. J. et al. Beta -blockade with nebivolol in elderly heart failure 
patients with impaired and preserved left ventricular ejection fraction: Data From 
SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53, 2150- 2158, 
doi:10.1016/j.jacc.2009.02.046 (2009).  
19 Pitt, B. et al. Spironolactone for heart  failure  with preserved ejection  fraction.  N Engl 
J Med 370, 1383-  1392, doi:10.1056/NEJMoa1313731  (2014).  
20 Redfield, M. M. et al. Effect of phosphodiesterase- 5 inhibition on exercise capacity 
and clinical status in heart failure with preserved ejection fraction: a randomized clinical  trial.  JAMA  309 , 1268- 1277,  
doi:10.1001/jama.2013.2024 (2013).  
21 Tseliou, E. et al. Fibroblasts Rendered Antifibrotic, Antiapoptotic, and 
Angiogenic by Priming  With Cardiosphere- Derived  Extracellular  Membrane 
Vesicles.  J Am CollCardiol 66, 599-611, doi:10.1016/j.jacc.2015.05.068 (2015).  
22 Zile, M. R. et al. Myocardial stiffness in patients  with heart failure and a preserved 
ejection fraction: contributions of collagen and titin. Circulation 131, 1247- 1259, 
doi:10.1161/CIRCULATIONAHA.114.013215 (2015).  
23 Kreke , M., Smith, R. R., Marban, L. & Marban, E. Cardiospheres and cardiosphere-  
derived cells astherapeutic agents following myocardial infarction. Expert Rev 
Cardiovasc Ther 10, 1185- 1194,doi:10.1586/erc.12.102 (2012).  
24 Zile, M. R. et al. Randomized, double- blind, placebo- controlled study of sitaxsentan 
to improveimpaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC HeartFail  2, 123-130, doi:10.1016/j.jchf.2013.12.002 (2014).  
25 Tschope, C. & Van Linthout, S. New insigh ts in (inter)cellular mechanisms by heart 
failure with preserved ejection fraction. Curr Heart Fail Rep 11, 436- 444, 
doi:10.1007/s11897- 014-0219- 3 (2014).  
66 
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
26 Mohammed, S. F. et al. Coronary microvascular rarefaction and myocardial fibrosis 
in heart failure with preserved ejection fraction. Circulation 131, 550- 559, 
doi:10.1161/CIRCULATIONAHA.114.009625 (2015).  
27 Yarbrough, W. M., Mukherjee, R., Ikonomidis, J. S., Zile, M. R. & Spinale, F. G. Myocardial remodeling with aortic stenosis and after aortic v alve replacement: 
mechanisms  and future  prognostic  implications.  J Thorac  Cardiovasc  Surg  143, 656- 
664, doi:10.1016/j.jtcvs.2011.04.044 (2012).  
28 Aminzadeh, M. A. et al. Therapeutic efficacy of cardiosphere- derived cells in a 
transgenic mouse model of non- ischaemic dilated cardiomyopathy. Eur Heart J 36, 
751-762, doi:10.1093/eurheartj/ehu196 (2015).  
29 Ibrahim, A. G., Cheng, K. & Marban, E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2, 606- 619, 
doi:10.1016/j.stemcr.2014.04.006 (2014).  
30 Smith, R. R. et al. Regenerative potential of cardiosphere- derived cells expanded 
from percutaneous endomyocardial biopsy specimens. Circulation 115, 896 -908, 
doi:10.1161/CIRCULATIONAHA.106.655209 (2007).  
31 Chimenti, I. et al . Relative roles of direct regeneration versus paracrine effects of 
human cardiosphere- derived cells transplanted into infarcted mice. Circ Res 106, 
971-980 (2010).  
32 Malliaras, K. et al. Safety and efficacy of allogeneic cell therapy in infarcted rats trans planted with mismatched cardiosphere- derived cells.  Circulation  125, 100-112, 
doi:10.1161/CIRCULATIONAHA.111.042598 (2012).  
33 Malliaras, K. et al. Validation of contrast -enhanced magnetic resonance imaging to 
monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial  infarction.  Circulation  128, 2764- 2775, 
doi:10.1161/CIRCULATIONAHA.113.002863 (2013).  
34 Marban, E. Breakthroughs in cell therapy for heart disease: focus on cardiosphere-  
derived cells. Mayo Clin Proc 89, 850- 858, doi:10.1016/j.mayocp.2014.02.014 
(2014).  
35 Makkar,  R. et al. ALLogeneic  Heart  STem  Cells  to Achieve  Myocardial  Regeneration 
(ALLSTAR): theOne Year Phase I Results Circulation 130 (2014).  
36 Solomon, S. D. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart 
failure with preserved ejection fraction: a phase 2 double -blind randomised 
controlled trial. Lancet 380, 1387- 1395, doi:10.1016/S0140- 6736(12)61227- 6 
(2012).  
37 Gaasch, W. H. & Zile, M. R. Left ventricular structural remodeling in health and disease: with specialemphasis on volume, mass, and geometry. J Am Coll Cardiol 58, 1733- 1740, doi:10.1016/j.jacc.2011.07.022 (2011).  
38 Zile, M. R. et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124, 2491- 2501,  doi:10.1161/CIRCULATIONAHA.110.011031 (2011).  
39 Kraigher -Krainer,  E. et al. Impaired systolic function by strain  imaging in heart  failure 
with preserved ejection fraction. J Am Coll Cardiol 63, 447- 456, 
doi:10.1016/j.jacc.2013.09.052 (2014).  
40 Santos,  A. B. et al. Impaired left atrial  function in heart  failure  with preserved ejection 
fraction.  Eur J Heart  Fail 16, 1096 -1103,  doi:10.1002/ejhf.147 (2014).  
 
67 
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
 
  
41 Shah, A. M. et al. Cardiac structure and function and prognosis in heart failure with 
preserved ejection fraction: findings from the echocardiographic study of the Treatment  of  Preserved  Cardiac  Function  Heart  Failure  with  an   Aldosterone  
42 Antagonist  (TOPCAT)  Trial.  Circ Heart  Fail 7, 740-751, 
doi:10.1161/CIRCHEARTFAILURE.114.001583 (2014).  
43 Zile, M. R., Baicu, C. F. & Gaasch, W. H. Diastolic heart failure --abnormalities in 
active relaxation and passive stiffness of the left ventricle. N Engl J Med 350, 1953-  
1959, doi:10.1056/NEJMoa032566 (2004).  
44 Abraham, W. T. et al. Wireless pulmonary artery haemodynamic monitoring in 
chronic heart failure: a randomised controlled trial. Lancet 377, 658- 666, 
doi:10.1016/S0140- 6736(11)60101- 3 (2011).  
45 Zile, M. R. et al. Transition from chronic compensated to acute decompensated 
heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac  pressures.  Circulation  118, 1433- 1441, 
doi:10.1161/CIRCULATIONAHA.108.783910 (2008).  
46 Adamson, P. B. et al. Hemodynamic factors associated with acute decompensated 
heart failure: part 2-- use in automated detection. J Card Fail 17, 366- 373, 
doi:10.1016/j.cardfail.2011.01.011 (2011).  
47 Zile, M. R. et al. Hemodynamic factors associated with acute decompensated heart 
failure: part 1 -- insights into pathophysiology. J Card Fail 17, 282- 291, 
doi:10.1016/j.cardfail.2011.01.010 (2011).  
48 Zile, M. R. et al. Plasma biomarkers that reflect determinants of matrix composition 
identify the presence of left v entricular hypertrophy and diastolic heart failure. Circ 
Heart Fail 4, 246- 256, doi:10.1161/CIRCHEARTFAILURE.110.958199 (2011).  
49 Zile, M. R. & Baicu, C. F. Biomarkers of diastolic dysfunction and myocardial fibrosis: 
application to heart failure with a pres erved ejection fraction. J Cardiovasc Transl 
Res 6, 501- 515, doi:10.1007/s12265- 013-9472- 1 (2013).  
50 Jhund, P. S. et al. Changes in N -terminal pro- B-type natriuretic peptide levels and 
outcomes in heart failure with preserved ejection fraction: an analysis of the I-  
Preserve study. Eur J Heart Fail 17, 809- 817, doi:10.1002/ejhf.274 (2015).  
51 Chow, S. et al. The Role of Biomarkers for the Prevention, Assessment, and 
Management of Heart Failure. A Consensus Statement for Healthcare Professions From the American H eart Association. Circulation In press (2015).  
52 Kallner, A. Microsoft EXCEL 2010 offers an improved random number generator 
allowing efficient simulation in chemical laboratory studies. Clin Chim Acta 438, 210- 211, doi:10.1016/j.cca.2014.08.036 (2015).  
53 Harrell, F. J. Regression Modeling Strategies. . (Springer -Verlag NY, Inc., 2001).  
54 GM, F., NM, L. & JH, W. Applied Longitudinal Analysis. . (New York: John Wiley & 
Sons, Inc. ,2004).  
55 Akaike, H. A new look at the statistical model identification. IEEE Transact ions on 
Automatic Control 19, 716- 723 (1974).  
56 Little, R. J. A. & Rubin, D. B. Statistical analysis with missing data, 2nd edition. . 
(New York: Wiley & Sons , 2002).  
57 Williamson, P. R., Kolamunnage- Dona, R., Philipson, P. & Marson, A. G. Joint 
modelling of longitudinal and competing risks data. Stat Med 27, 6426- 6438, 
doi:10.1002/sim.3451 (2008).  
 
68
Confidential   October 12, 2020  IND Submission: Revision #3  
Allogeneic Cardiosphere- Derived Cells(CAP1002)  
October 12, 2020 
  
  
58 Gallet, R, de Couto, G. et al. Cardiosphere- derived cells reverse heart failure with 
preserved ejection fraction (HFpHF) in rats by decreasing fibrosis and inflammation. 
JACC HeartFail. In press  (2016).  
 
59 Chakravarty, T, R. R. Makkar, M. Kittleson, J. Friedman, D.Berman, R. George, R.Siegel, L. Slipczuk, A. Hamer, R. R. Smith, S. Smith, K. Kacena, L. Marbán, T.D Henry, and E. Marbán “Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally -regenerative Cells (DYNAMIC): Six Month Safety and Explor atory 
Efficacy Results”. Circulation.  2015;132:A18236,  
 
 
 
  
 
  
 
  
 
  
 
 
 
 
 
 
  
 
  
 
 
69 